🏷

Classifications

Harrison's Part

🔗

Mappings

MONDO

MONDO:0001003 pneumoconiosis due to talc

Primary MONDO disease identifier for pneumoconiosis due to talc.

📘

Definitions

2

Clinical and pathological case definition for talc pneumoconiosis

Talc pneumoconiosis is a silicatosis: a dust disease of the lung following deposition of respirable talc, defined by a documented exposure together with the characteristic pathology of dust-laden macrophages, birefringent particles, foreign-body giant cells and centrilobular interstitial fibrosis.

CASE_DEFINITION Disease-level framing within the silicate pneumoconioses

Show evidence (2 references)

PMID:39030439 SUPPORT Other

"Silicatosis is a lung condition caused by inhalation of silicates, which comprises silicates such as talc, mica, and kaolinite"

Places talc among the silicates whose inhalation causes silicatosis, which is the disease family this entry sits in.

PMID:39030439 SUPPORT Other

"At histology, focal peribronchial and perivascular fibrosis is associated with abundant dust deposits containing needle-shaped bluish-gray birefringent particles associated with giant cell response"

States the defining histological combination of birefringent dust deposits, giant cell reaction and focal fibrosis.

Histopathological diagnostic criteria for talc pneumoconiosis

Diagnosis rests on polarized light microscopy demonstrating birefringent silicate crystals within centrilobular fibrotic areas, together with the stellate pattern of centrilobular interstitial fibrosis described as a medusa head. Morphology alone does not identify the mineral, so exposure history and mineral analysis remain necessary.

DIAGNOSTIC_CRITERIA Pathological recognition and the limits of morphology alone

Show evidence (3 references)

PMID:39030439 SUPPORT Other

"Polarized light microscopy: birefringent crystals (silicates) in the centrilobular fibrotic brown areas of silicatosis."

States the specific polarized-light finding used diagnostically.

PMID:34401315 SUPPORT Human Clinical

"Biopsy samples revealed abundant macrophages with white crystals that were negatively birefringent under polarized light indicative of talc crystals"

A worked application of the same technique, here establishing the diagnosis after an inhalational cosmetic exposure.

PMID:39030439 SUPPORT Other

"The typical features comprise patchy and stellate-shaped centrilobular interstitial fibrosis (so-called "medusa head") composed of a mixture of fibroblasts, collagen fibres, and dust-filled macrophages."

States the characteristic stellate centrilobular fibrosis pattern and its cellular composition.

◆

Subtypes

2

Inhalational talcosis (occupational or cosmetic dust exposure)

The pneumoconiosis proper. Respirable talc dust inhaled during mining, milling, bagging and manufacture, or during heavy cosmetic powder use, deposits in distal airways and the interstitium and produces centrilobular granulomas with stellate interstitial fibrosis. Mortality from pneumoconiosis is markedly raised in talc-industry cohorts.

Show evidence (2 references)

PMID:32816595 SUPPORT Other

"The industrial mining, milling, and processing of talc ore is associated with elevated incidences of fibrotic and neoplastic diseases, which are also seen among workers exposed to RTP in secondary industries and individuals using processed cosmetic talc for personal use."

Supports both the occupational and the cosmetic inhalational routes belonging to this subtype.

PMID:36287869 SUPPORT Human Clinical

"There was increased mortality for pneumoconiosis, especially in the miner's group (SMR = 7.90, CI 95% 2.77-22.58) and especially in those exposed to higher quartz concentration"

Quantifies the pneumoconiosis mortality excess in occupationally exposed cohorts, and records that it was greatest where quartz co-exposure was higher.

Intravascular talcosis (injected tablet excipients)

An anatomically distinct disease reached by a different route. Crushed oral tablets injected intravenously deliver talc together with other insoluble excipients into the pulmonary vasculature, where they embolize and provoke perivascular foreign-body granulomas. Granulomas sit close to the pulmonary vessels rather than in the centrilobular interstitium, and the disease can progress to pulmonary arterial hypertension.

Show evidence (2 references)

PMID:40881529 SUPPORT Human Clinical

"Pulmonary talcosis is a rare granulomatous lung disease resulting from the intravenous injection of crushed oral tablets containing insoluble excipients such as talc, microcrystalline cellulose, and crospovidone."

Defines this subtype by its exposure route and records that the injected material is a mixture of excipients rather than talc alone.

PMID:39030439 SUPPORT Other

"talc is a frequent filler in medications used for oral consumption or may reach the lungs by the vascular route in drug abusers (intravenous injection of crushed tablets; in this case the talc granulomas are localized close to the pulmonary vasculature)"

States the anatomical distinction that separates this subtype from the inhalational form, with granulomas localized to the pulmonary vasculature.

?

Discussions and Knowledge Gaps

1

Is the fibrosis of occupational talc pneumoconiosis caused by talc itself, or by the quartz and amphibole minerals that accompany commercial talc ore?

CONTROVERSY OPEN talc-vs-contaminant-attribution

Attached to

pathophysiology#Respirable talc deposition in the distal lung pathophysiology#Stellate centrilobular interstitial fibrosis

The question is not settled and it bears directly on every causal edge in the inhalational branch of this entry. Commercial respirable talc is a mineral mixture that can include tremolite, anthophyllite and quartz, and the pneumoconiosis mortality excess in talc-industry cohorts was highest where quartz content was higher, which is what a contaminant effect would look like. Against a pure-contaminant explanation, the Vermont cohort was explicitly exposed to ore free of asbestos and silica and still showed radiographic opacities in never-smokers and an exposure effect on lung function after adjusting for smoking; and the hamster instillation study characterized its material with asbestos and quartz below detection. The entry therefore asserts a talc-attributable mechanism, while recording that the magnitude of the occupational disease burden cannot be attributed to talc alone from the available cohorts.

Show evidence (3 references)

PMID:32816595 SUPPORT Other

"There is controversial evidence of a link between the talc-induced lung diseases and a potential contamination with asbestos fibers."

States that the contamination link is itself controversial, which is the controversy this discussion records.

PMID:32816595 SUPPORT Other

"This controversy is fueled by inadequate exposure data and the complex mineralogy and terminology of the accessory minerals."

Names the reasons the question remains open, namely exposure data quality and mineralogical complexity.

PMID:7093149 SUPPORT Human Clinical

"There was evidence of an exposure effect after adjusting for cigarette smoking and we conclude that these workers have been affected by their exposures."

The strongest evidence on the talc-attributable side, from a cohort whose ore was free of asbestos and silica.

⚙

Pathophysiology

6

Respirable talc deposition in the distal lung

Inhaled respirable talc deposits in the distal airways and the alveolar-interstitial compartment. The inhaled material is not pure: a substantial fraction behaves as fibres rather than compact particles, and commercial talc ore carries accessory minerals including tremolite, anthophyllite and quartz.

response to toxic substance GO:0009636 ↑ INCREASED

lung UBERON:0002048 terminal bronchiole UBERON:0002187

Downstream

Alveolar macrophage uptake with impaired clearance Deposited particles are phagocytosed by alveolar macrophages, but cleared poorly.

Show evidence (2 references)

PMID:32816595 SUPPORT Other

"Respirable talc powder (RTP) is a complex mineral mixture of talc along with accessory minerals, including tremolite, anthophyllite, quartz, magnesite, dolomite, antigorite, lizardite, and chlorite."

Establishes that the deposited material is a mineral mixture, which is what makes the attribution of downstream injury to talc alone difficult.

PMID:32498698 SUPPORT Model Organism

"fibers with aspect ratios 3:1 accounted for 22% of instilled material, mostly as fibrous talc"

Quantifies the fibrous fraction of the instilled talc, which is the dimensional property relevant to deposition and clearance.

Alveolar macrophage uptake with impaired clearance

Alveolar macrophages phagocytose talc particles, but clearance falls away over time: in hamsters, initial uptake of talc was high yet by two weeks phagocytosis by lavaged cells was significantly lower than for granite dust. Particles end up not only in macrophages but in neutrophils and multinucleate giant cells.

alveolar macrophage CL:0000583 neutrophil CL:0000775

macrophage activation GO:0042116 ↑ INCREASED inflammatory response GO:0006954 ↑ INCREASED

Animal models

Hamster intratracheal talc instillation model Hamster recapitulates Reproduces macrophage phagocytosis of talc and the subsequent decline in clearance, with particles appearing in macrophages, neutrophils and giant cells.

Downstream

Foreign-body giant cell granuloma formation Poorly cleared particles drive a multinucleate foreign-body giant cell reaction.

Show evidence (4 references)

PMID:32498698 SUPPORT Model Organism

"over the 14-day experiment, talc phagocytosis by lavaged cells was significantly less than that of granite"

Directly supports failing particle clearance over two weeks, which is what allows retention rather than resolution.

PMID:32498698 SUPPORT Model Organism

"birefringent particles were found in macrophages, neutrophils, and multinucleate giant cells in lavaged cells from talc-exposed animals"

Supports particle handling by three cell populations, including the giant cells that define the next step.

PMID:32498698 SUPPORT Model Organism

"BAL cell counts confirmed the presence of acute inflammation, which followed intratracheal instillation."

The measured inflammatory response behind this node's macrophage activation and inflammatory response terms, which no other snippet here states.

+ 1 more reference

Foreign-body giant cell granuloma formation

Retained birefringent particles sit within granulomas formed by multinucleated foreign-body giant cells. On biopsy these appear as giant cell granulomas containing birefringent material, and under polarized light the crystals are visible inside the fibrotic areas.

multinucleated giant cell CL:0000647

granuloma formation GO:0002432 ↑ INCREASED

lung UBERON:0002048

Downstream

Stellate centrilobular interstitial fibrosis Persistent granulomatous inflammation organizes into centrilobular interstitial fibrosis.

Granulomatosis The granulomatous reaction is itself the clinically and radiologically recognized lesion.

Show evidence (4 references)

PMID:39030439 SUPPORT Other

"At histology, focal peribronchial and perivascular fibrosis is associated with abundant dust deposits containing needle-shaped bluish-gray birefringent particles associated with giant cell response"

Supports the giant cell response accompanying the dust deposits as the characteristic histology.

PMID:27446215 SUPPORT BACKGROUND Human Clinical

"Inhalational talc has been associated with histological patterns of diffuse interstitial fibrosis, nodular fibrosis, and foreign body granulomatosis"

Names foreign-body granulomatosis as a histological pattern of inhalational talc specifically, which is the route this branch models.

PMID:34401315 SUPPORT BACKGROUND Human Clinical

"Once in the lungs, talc can cause non-necrotizing granulomas to form"

States granuloma formation as the consequence of talc reaching the lung, for the inhalational route.

+ 1 more reference

Stellate centrilobular interstitial fibrosis

Fibroblasts and collagen accumulate around the retained dust, producing the patchy stellate centrilobular interstitial fibrosis that defines the silicatoses. Focal peribronchial and perivascular fibrosis accompanies it.

fibroblast CL:0000057

collagen fibril organization GO:0030199 ↑ INCREASED extracellular matrix organization GO:0030198 ↑ INCREASED

lung connective tissue UBERON:0000114

Downstream

Pulmonary fibrosis The lesion presents clinically and radiologically as pulmonary fibrosis.

Small rounded and irregular radiographic opacities The fibrotic lesion and its retained dust are what the radiograph shows as small irregular opacities.

Dyspnea Fibrosis impairs ventilation and gas transfer, producing breathlessness.

Cough The fibrotic and granulomatous lesion provokes the chronic cough patients present with.

Reduced forced expiratory volume in one second Fibrosis and airway damage reduce measured expiratory flow over time.

Show evidence (1 reference)

PMID:39030439 SUPPORT Other

"Silicatosis or other rare forms of dust: stellate-shaped centrilobular interstitial fibrosis composed of a mixture of fibroblasts, collagen fibres, and dust-filled macrophages."

Directly supports the fibrotic lesion and names its fibroblast and collagen composition.

Intravascular excipient embolization

The alternative route. Crushed oral tablets injected intravenously deliver talc together with microcrystalline cellulose and crospovidone into the pulmonary circulation, where the insoluble particles embolize in arterioles and capillaries. Because the injected material is a mixture, a birefringent particle on biopsy does not establish that the agent was talc.

response to toxic substance GO:0009636 ↑ INCREASED

pulmonary artery UBERON:0002012

Downstream

Perivascular foreign-body granulomatosis Embolized particles provoke granulomatous inflammation around the pulmonary vessels.

Show evidence (1 reference)

PMID:40881529 SUPPORT Human Clinical

"These substances embolize within the pulmonary vasculature, provoking granulomatous inflammation that may progress to pulmonary arterial hypertension (PAH)."

Directly supports embolization of the injected excipients within the pulmonary vasculature as the initiating step of this branch.

Perivascular foreign-body granulomatosis

Granulomas form around and within the pulmonary arterioles rather than in the centrilobular interstitium, which is the anatomical signature separating this branch from the inhalational disease. Radiologically this appears as centrilobular nodules that spare the subpleural regions and fissures.

multinucleated giant cell CL:0000647

granuloma formation GO:0002432 ↑ INCREASED

pulmonary artery UBERON:0002012

Downstream

Pulmonary arterial hypertension Granulomatous involvement of the pulmonary arterioles raises pulmonary vascular resistance.

Centrilobular nodules on computed tomography The particles lodged in the centrilobular arterioles and perivascular space are what computed tomography resolves as centrilobular nodules.

Granulomatosis The perivascular granulomas are the recognized lesion of this branch.

Show evidence (2 references)

PMID:39030439 SUPPORT Other

"in this case the talc granulomas are localized close to the pulmonary vasculature"

Directly supports the perivascular localization that distinguishes this branch anatomically.

PMID:28538785 SUPPORT Human Clinical

"The centrilobular nodules were determined histopathologically to be tiny foreign body particles lodged in the centrilobular arterioles and perivascular space."

Human histopathology of the perivascular and intra-arteriolar particle location.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

9

Blood 1

Granulomatosis HP:0002955

Show evidence (1 reference)

PMID:28538785 SUPPORT Human Clinical

"Transbronchial biopsy performed in the left lower lobe showed multinucleated giant cell granulomas with birefringent foreign material, compatible with talc"

Human biopsy confirmation of giant cell granulomas with birefringent material.

Cardiovascular 1

Pulmonary arterial hypertension HP:0002092

Show evidence (5 references)

PMID:40881529 SUPPORT Human Clinical

"These substances embolize within the pulmonary vasculature, provoking granulomatous inflammation that may progress to pulmonary arterial hypertension (PAH)."

Supports pulmonary arterial hypertension as a documented consequence of the intravascular form.

PMID:40881529 SUPPORT Human Clinical

"Imaging revealed elevated right ventricular pressures and computed tomography (CT) findings of centrilobular nodules with sparing of the subpleural regions and fissures, characteristic of talc granulomatosis."

Documents the measured right ventricular pressure elevation in a confirmed case.

PMID:27446215 SUPPORT Human Clinical

"consistent with severe pulmonary hypertension"

Severe pulmonary hypertension on echocardiography in a patient whose talc exposure was inhaled cosmetic powder rather than injection. Read with its confounders: this man was 82 with chronic obstructive pulmonary disease, 30 pack-years and terminal leukaemia, and his talcosis was a clinical diagnosis because biopsy was not pursued, so his pulmonary hypertension has competing causes. The biopsy-confirmed case below is the stronger support for unscoping this phenotype.

+ 2 more references

Respiratory 7

Dyspnea HP:0002094

Show evidence (2 references)

PMID:28538785 SUPPORT Human Clinical

"A 38-year-old woman presented to our pulmonology clinic with complaints of progressive dyspnea and dry cough for more than three months."

Documents progressive dyspnea as the presenting complaint in a confirmed case.

PMID:34401315 SUPPORT BACKGROUND Human Clinical

"the presenting symptoms of pulmonary talcosis are nonspecific and include dyspnea on exertion, cough, weight loss, anorexia, and diaphoresis"

Names dyspnea as a presenting symptom of the disease generally, including the inhalational route, so this phenotype does not rest on an injection case alone.

Cough HP:0012735

Show evidence (2 references)

PMID:28538785 SUPPORT Human Clinical

"complaints of progressive dyspnea and dry cough for more than three months"

Documents dry cough alongside dyspnea in a confirmed case.

PMID:34401315 SUPPORT BACKGROUND Human Clinical

"the presenting symptoms of pulmonary talcosis are nonspecific and include dyspnea on exertion, cough, weight loss, anorexia, and diaphoresis"

Names cough among the presenting symptoms of the disease generally, not only of the injection form.

Pulmonary fibrosis HP:0002206

Show evidence (4 references)

PMID:39030439 SUPPORT Other

"Silicatosis or other rare forms of dust: stellate-shaped centrilobular interstitial fibrosis composed of a mixture of fibroblasts, collagen fibres, and dust-filled macrophages."

Supports interstitial fibrosis as the characteristic lesion of the silicatoses including talcosis.

PMID:40881529 SUPPORT Human Clinical

"this process can result in PAH and interstitial fibrosis"

Supports interstitial fibrosis as an outcome of the intravascular route too, which is why this phenotype is not scoped to the inhalational subtype.

PMID:28538785 SUPPORT Human Clinical

"Over time, talc micronodules may coalesce into perihilar conglomerate masses, resembling progressive massive fibrosis from silicosis or coal workers' pneumoconiosis."

Supports coalescence of the nodular lesions into conglomerate masses, the advanced form of the fibrotic phenotype.

+ 1 more reference

Lower lobe panacinar emphysema HP:0032967

Show evidence (2 references)

PMID:40881529 SUPPORT Human Clinical

"high-resolution computed tomography (HRCT) can demonstrate nodular opacities, diffuse ground-glass patterns, and lower lobe-predominant panacinar emphysema"

States lower lobe-predominant panacinar emphysema among the imaging findings of this presentation.

PMID:40881529 SUPPORT Human Clinical

"In advanced cases, manifestations may include cor pulmonale, panlobular emphysema"

Supports emphysema as a manifestation of advanced disease, under its panlobular synonym.

Reduced forced expiratory volume in one second HP:0032342

Show evidence (1 reference)

PMID:7093149 SUPPORT Human Clinical

"Pulmonary function values at the time of the initial study were less than predicted and the rates of loss of FEV1 and FVC greater than expected."

Supports reduced and declining expiratory volume in a cohort exposed to talc free of asbestos and silica.

Small rounded and irregular radiographic opacities Diffuse reticular or finely nodular infiltrations HP:0002207

Show evidence (2 references)

PMID:7093149 SUPPORT Human Clinical

"Of the 12 subjects whose chest radiographs showed small round or irregular opacities (perfusion 1/0 or greater), five had never smoked cigarettes."

Supports radiographic opacities in exposed workers, including never-smokers.

PMID:39030439 SUPPORT Other

"Clinical and functional features are similar to silicosis, whereas the radiographic opacities are more irregular."

Supports the irregular character of the opacities, which is what distinguishes them radiographically from silicosis.

Centrilobular nodules on computed tomography Nodular pattern on pulmonary HRCT HP:0025392

Show evidence (4 references)

PMID:40881529 SUPPORT Human Clinical

"Imaging revealed elevated right ventricular pressures and computed tomography (CT) findings of centrilobular nodules with sparing of the subpleural regions and fissures, characteristic of talc granulomatosis."

States the computed tomography pattern and its distribution in an intravascular case.

PMID:28538785 SUPPORT Human Clinical

"The centrilobular nodules were determined histopathologically to be tiny foreign body particles lodged in the centrilobular arterioles and perivascular space."

Ties the nodules seen on imaging to the particles lodged in the centrilobular arterioles.

PMID:34401315 SUPPORT BACKGROUND Human Clinical

"Chest CT in patients who inhale talc is typically characterized by middle- or upper-lobe predominant centrilobular nodules and ground glass opacities"

States the inhalational distribution, which is why this phenotype is no longer scoped to the intravascular subtype.

+ 1 more reference

💊

Medical Actions

3

Cessation of talc exposure

Action: talc dust exposure avoidance Ontology label: Lifestyle Therapy NCIT:C15900

Platform: Behavioral / lifestyle

Removing the exposure is the only intervention that acts on the cause. No treatment reverses established fibrosis, and spontaneous resolution of established fibrosis is not established, so prevention of further deposition is the actionable step. Cessation is not a cure: established disease is reported to progress even after every exposure has stopped.

Mechanism Target:

INHIBITS Respirable talc deposition in the distal lung — Ending the exposure prevents further deposition and retention of dust.

Show evidence (1 reference)

PMID:7093149 SUPPORT INDIRECT Human Clinical

"Populations such as this will need to be studied for longer periods to determine what current dust levels are safe."

Graded INDIRECT because the source argues for dust-level control as the unresolved preventive question rather than measuring the effect of cessation on an individual's disease.

Show evidence (3 references)

PMID:28538785 SUPPORT Human Clinical

"Patients must stop exposure and all tobacco use."

States the cessation recommendation directly. Note the source is an intravenous case report, so the explicit recommendation in the literature comes from the injection setting; the occupational arm of this treatment rests on the dust-level evidence cited on the mechanism link.

PMID:40881529 SUPPORT Human Clinical

"Management primarily involves supportive care and cessation of intravenous drug use."

States cessation of the exposure as the mainstay of management, again from the intravenous literature.

PMID:34401315 REFUTE BACKGROUND Human Clinical

"There is no specific treatment. The disease may continue to progress even if all talc exposures have ceased"

Counterweight to reading cessation as disease-modifying. Progression after complete cessation is reported, so this treatment prevents further deposition rather than arresting the disease.

Supportive management of established disease

Action: Supportive Care NCIT:C15747

Platform: Other

Management of established talcosis is supportive, directed at symptoms, oxygenation and any pulmonary hypertension rather than at the retained dust. In the reported intravascular case, oxygen, antiplatelet therapy and oral sildenafil improved symptoms.

Mechanism Target:

MODULATES Pulmonary arterial hypertension — Pulmonary vasodilator therapy addresses the raised pulmonary arterial pressure rather than the granulomas causing it.

Show evidence (1 reference)

PMID:40881529 SUPPORT Human Clinical

"Pulmonary hypertension associated with this condition may be managed with vasodilators; in some cases, oral sildenafil has shown promise."

States vasodilator therapy as the management of the pulmonary hypertension of this condition, which supports the edge more directly than one patient's regimen does.

Show evidence (1 reference)

PMID:40881529 SUPPORT Human Clinical

"The patient was managed with supplemental oxygen, antiplatelet therapy, and oral sildenafil, resulting in symptomatic improvement"

Supports supportive and vasodilator management as the reported approach in established disease.

Lung transplantation for end-stage disease

Action: lung transplantation Ontology label: Organ Transplantation NCIT:C15289

Platform: Surgery

Where disease is end-stage and unresponsive to medical therapy, lung transplantation is reported as an option. It does not act on the retained dust or the granulomatous reaction; it replaces the organ they have damaged.

Mechanism Target:

BYPASSES Stellate centrilobular interstitial fibrosis — Replacing the lung bypasses the fibrotic lesion rather than reversing it.

Show evidence (1 reference)

PMID:40881529 SUPPORT INDIRECT Human Clinical

"Lung transplantation may be considered in patients with end-stage disease unresponsive to medical therapy"

Graded INDIRECT because the source states transplantation as an option in end-stage disease without reporting an outcome against the fibrotic lesion itself.

Show evidence (1 reference)

PMID:28538785 SUPPORT Human Clinical

"Lung transplantation is considered to be a viable option for the treatment of talcosis."

States transplantation as a treatment option for talcosis.

🌍

Environmental Factors

4

Non-occupational inhalation of cosmetic and household talcum powder

Neither source claims cosmetic talc is hazardous in ordinary use. The second states plainly that there is no substantial evidence that cosmetic talc presents a health hazard when used as intended; both reported cases involved heavy or deliberate inhalation. The entry records the route without asserting a risk at normal use.

Talc in cosmetic face powder, body powder and baby powder is inhaled during application. Two reported cases reached pulmonary talcosis this way: a woman who applied talcum face powder excessively for two years, and a man who deliberately inhaled scented talcum powder over years. This route is inhalational, so it belongs to the same subtype as the occupational dust, but it reaches people with no industrial history at all, which is why both cases were first misdiagnosed. The first was confirmed on transbronchial biopsy; the second was a clinical and radiological diagnosis, biopsy having been ruled out by thrombocytopenia, so it is the weaker of the two.

Show evidence (4 references)

PMID:34401315 SUPPORT Human Clinical

"the patient admitted to excessive application of talcum face powder for two years prior to her presentation"

The exposure history that established the diagnosis in a woman with no occupational or injection exposure.

PMID:27446215 SUPPORT Human Clinical

"he would often inhale lavender-scented talcum powder for relaxation during his business trips for an unspecified number of years"

A second non-occupational inhalational exposure, here deliberate inhalation rather than cosmetic application.

PMID:34401315 SUPPORT BACKGROUND Other

"talc exposure from household products is often overlooked as a causative agent of inhalation pneumoconiosis"

States why this route matters clinically. Kept at OTHER because the sentence is the authors' judgement about clinical attention rather than a description of evidence, with quote_role BACKGROUND because it is framing rather than their own case finding.

+ 1 more reference

Mechanism Target:

TRIGGERS Respirable talc deposition in the distal lung — Inhalation during cosmetic application or deliberate use delivers respirable talc to the distal lung.

Show evidence (1 reference)

PMID:34401315 SUPPORT Human Clinical

"Biopsy samples revealed abundant macrophages with white crystals that were negatively birefringent under polarized light indicative of talc crystals"

Confirms talc actually reached and was retained in the distal lung by this route, on biopsy.

Ambient fibrous talc in non-occupationally exposed lungs

Deliberately carries no influences_mechanisms link, so it does not appear in the pathograph. The only claim the source supports is that fibrous talc is found in some lungs without occupational exposure. It is a case-control count of lung fibres: it does not show that ambient air was the route, and it says nothing about this disease, so an edge into the deposition node would add a claim rather than evidence. The entry is kept as context for non-occupational exposure, alongside the cosmetic-powder route, which does have case-level evidence for its route.

Fibrous talc is recoverable from the lungs of Japanese women with no occupational exposure. The reported comparison is narrower than it first looks: fibrous talc counts were higher in urban lung cancer cases than in urban non-cancer, rural cancer and rural non-cancer cases, so the contrast is cancer-stratified and is not a general urban-versus-rural one. The study did not assess talcosis.

Show evidence (2 references)

PMID:9222135 SUPPORT Human Clinical

"Amosite/crocidolite and fibrous talc counts in urban lung cancer cases were greater than those of urban non-lung cancer cases, rural lung cancer, and rural non-lung cancer cases"

Measures fibrous talc in lung tissue from women without occupational exposure. Note what the comparison is: urban lung cancer cases against the other three groups. It does not compare urban non-cancer with rural cases, so it does not establish a general urban excess, and it does not identify ambient air as the source of the talc.

PMID:9222135 NO_EVIDENCE Human Clinical

"fibrous talc in urban environments may be another candidate for carcinogenic or cocarcinogenic factors of female lung cancer"

Recorded as NO_EVIDENCE for this entry's claims. The authors raise ambient fibrous talc as a candidate lung-cancer factor; that is a hypothesis about a different disease, and this entry neither asserts nor relies on it.

Occupational inhalation of respirable talc dust

Mining, crushing, milling, bagging and manufacture of talc-containing products generate respirable talc dust. Pneumoconiosis mortality is markedly raised in these cohorts, most of all among miners and in cohorts with higher quartz content.

Show evidence (2 references)

PMID:32816595 SUPPORT Other

"The industrial mining, milling, and processing of talc ore is associated with elevated incidences of fibrotic and neoplastic diseases, which are also seen among workers exposed to RTP in secondary industries and individuals using processed cosmetic talc for personal use."

Supports industrial talc processing as the principal occupational exposure route.

PMID:36287869 SUPPORT Human Clinical

"There was increased mortality for pneumoconiosis, especially in the miner's group (SMR = 7.90, CI 95% 2.77-22.58) and especially in those exposed to higher quartz concentration"

Quantifies the mortality consequence of this exposure, and records the quartz-dependence that complicates attributing it to talc.

Mechanism Target:

TRIGGERS Respirable talc deposition in the distal lung — Occupational dust generation delivers respirable talc to the distal lung.

Show evidence (1 reference)

PMID:7093149 SUPPORT Human Clinical

"There was evidence of an exposure effect after adjusting for cigarette smoking and we conclude that these workers have been affected by their exposures."

Supports the occupational exposure itself producing respiratory effect, in a cohort where asbestos and silica were absent from the ore.

Intravenous injection of crushed oral tablets

Injection of crushed tablets intended for oral use delivers talc filler, with other insoluble excipients, directly into the venous circulation and so into the pulmonary arterioles. This is not an occupational pneumoconiosis and its pathology is perivascular rather than centrilobular.

Show evidence (2 references)

PMID:40881529 SUPPORT Human Clinical

"Pulmonary talcosis is a rare granulomatous lung disease resulting from the intravenous injection of crushed oral tablets containing insoluble excipients such as talc, microcrystalline cellulose, and crospovidone."

Supports injection of crushed oral tablets as the exposure route for this branch, and names the excipient mixture delivered.

PMID:39030439 SUPPORT Other

"talc is a frequent filler in medications used for oral consumption or may reach the lungs by the vascular route in drug abusers (intravenous injection of crushed tablets; in this case the talc granulomas are localized close to the pulmonary vasculature)"

Supports the vascular delivery route and its distinct perivascular pathology.

Mechanism Target:

TRIGGERS Intravascular excipient embolization — Injection places insoluble particles in the venous return, which carries them to the pulmonary arterioles.

Show evidence (1 reference)

PMID:40881529 SUPPORT Human Clinical

"These substances embolize within the pulmonary vasculature, provoking granulomatous inflammation that may progress to pulmonary arterial hypertension (PAH)."

Supports the exposure initiating embolization within the pulmonary vasculature.

📈

Progression

4

Variable latency from exposure to symptoms

The interval between exposure and symptoms is not fixed. Reported cases span months to four decades, so a remote exposure does not exclude the diagnosis and a recent one does not date the disease.

Show evidence (1 reference)

PMID:34401315 SUPPORT BACKGROUND Human Clinical

"Among documented cases, there have been patients who manifested symptoms only months after exposure, as well as those who became symptomatic up to four decades after exposure"

States the latency range across the reported literature. quote_role BACKGROUND because it summarizes other authors' cases rather than this one; those cases are human, which is what evidence_source grades.

Particle retention with radiographic opacities

The earliest recognized stage is retained dust with small round or irregular radiographic opacities, which can be present in workers who have never smoked and before symptoms dominate.

Show evidence (1 reference)

PMID:7093149 SUPPORT Human Clinical

"Of the 12 subjects whose chest radiographs showed small round or irregular opacities (perfusion 1/0 or greater), five had never smoked cigarettes."

Supports an early radiographic stage, and establishes it in never-smokers so that smoking does not explain it away.

Accelerated loss of lung function

Function declines faster than predicted, and the excess persists after adjusting for cigarette smoking, which is what identifies the dust exposure rather than tobacco as the driver.

Show evidence (2 references)

PMID:7093149 SUPPORT Human Clinical

"Pulmonary function values at the time of the initial study were less than predicted and the rates of loss of FEV1 and FVC greater than expected."

Supports progressive functional decline measured over follow-up in an exposed cohort.

PMID:7093149 SUPPORT Human Clinical

"There was evidence of an exposure effect after adjusting for cigarette smoking and we conclude that these workers have been affected by their exposures."

Supports attribution of the decline to the dust exposure rather than to smoking.

Variable course after exposure ends in the intravascular form

One reported intravascular case was followed for three years with clinical stability and no disease-specific treatment, so established disease is not invariably progressive. That is a single case, and it is not the usual account: the review of this presentation states that most patients decline. Both are recorded here rather than one standing for the course.

Show evidence (2 references)

PMID:28538785 SUPPORT Human Clinical

"During 3 years of follow-up, the patient showed clinical stability with the persistence of dyspnea on exertion and dry cough."

Documents three years of clinical stability, with persistent symptoms, in one intravascular case.

PMID:40881529 REFUTE Human Clinical

"It is important to note that most patients have a poor prognosis due to the progressive decline in pulmonary function."

Counterweight to the phase as stated. If most patients decline progressively, a stable three-year course is not the typical outcome, and this phase should be read as one documented possibility.

🔀

Differential Diagnoses

1

Conditions with similar clinical presentations that must be differentiated from Talc Pneumoconiosis:

Silicosis

Distinguishing Features

Both are mineral dust pneumoconioses and talc ore frequently carries quartz, so the two can coexist in one patient
Talcosis shows needle-shaped bluish-gray birefringent particles with a giant cell response
Where crystalline silica is a substantial accompaniment the disease is termed talcosilicosis rather than talcosis

Show evidence (2 references)

PMID:39030439 SUPPORT Other

"At histology, focal peribronchial and perivascular fibrosis is associated with abundant dust deposits containing needle-shaped bluish-gray birefringent particles associated with giant cell response"

Supports the particle morphology and giant cell reaction that identify talc rather than silica on biopsy.

PMID:36287869 SUPPORT Human Clinical

"especially in those exposed to higher quartz concentration"

Supports quartz co-exposure as a real and quantitatively important confounder, which is why these two diseases have to be distinguished deliberately.

🐁

Animal Models

1

Hamster intratracheal talc instillation model

Male hamsters given a single intratracheal instillation of talc and followed for 14 days, with bronchoalveolar lavage cells examined by polarized light microscopy. The instilled material was characterized by scanning electron microscopy with energy-dispersive x-ray analysis, and asbestos and quartz were below detection, which is what makes this a talc-attributable observation rather than a mixed-mineral one.

Species

Hamster

Publication

PMID:32498698

Pathograph links

Alveolar macrophage uptake with impaired clearance recapitulates fidelity: moderate observes: cellular Reproduces macrophage phagocytosis of talc and the subsequent decline in clearance, with particles appearing in macrophages, neutrophils and giant cells.

Limitations: Intratracheal instillation is a bolus delivery that does not reproduce aerosol deposition during chronic occupational inhalation, the follow-up is only 14 days against a human disease of years, only male animals were used, and hamster particle clearance differs from human.

Readouts

Phagocytosis of birefringent talc particles by lavaged cells

Direction: DECREASED

Interpretation: Falling particle uptake over 14 days, the clearance failure this node asserts.

Show evidence (1 reference)

PMID:32498698 SUPPORT Model Organism

"over the 14-day experiment, talc phagocytosis by lavaged cells was significantly less than that of granite"

Reports the measured decline in talc phagocytosis relative to a comparator dust.

Show evidence (1 reference)

PMID:32498698 SUPPORT Model Organism

"Phagocytosis of talc fibers by macrophages was observed"

Supports treating this model as informative for the macrophage uptake node.

Show evidence (1 reference)

PMID:32498698 SUPPORT Model Organism

"birefringent particles were found in macrophages, neutrophils, and multinucleate giant cells in lavaged cells from talc-exposed animals"

Characterizes the cellular distribution of retained particles in this model.

{ }

Source YAML

click to show

name: Talc Pneumoconiosis
creation_date: "2026-10-07T17:11:49Z"
category: Environmental
categories:
- Occupational Lung Disease
- Pneumoconiosis
- Toxic Exposure Disorder
synonyms:
- talcosis
- inhalational talcosis
- talc pneumoconiosis
- pulmonary talcosis
description: >-
  Talc pneumoconiosis is a mineral dust lung disease caused by deposition of
  respirable talc, a hydrated magnesium silicate. Retained particles are taken up
  by alveolar macrophages but cleared poorly, provoking a foreign-body giant cell
  reaction and centrilobular granulomas that progress to stellate interstitial
  fibrosis. Two routes deliver talc to the lung and produce anatomically distinct
  disease: occupational or heavy cosmetic inhalation deposits dust in the distal
  airways and interstitium, whereas intravenous injection of crushed oral tablets
  embolizes talc and other insoluble excipients into pulmonary arterioles,
  producing perivascular granulomas that can lead to pulmonary arterial
  hypertension. A persistent attribution problem runs through the occupational
  literature, because commercial talc ore frequently carries quartz and amphibole
  minerals whose own fibrogenicity is not separable from talc's in most cohorts.
disease_term:
  preferred_term: pneumoconiosis due to talc
  term:
    id: MONDO:0001003
    label: pneumoconiosis due to talc
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0001003
      label: pneumoconiosis due to talc
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: Primary MONDO disease identifier for pneumoconiosis due to talc.
classifications:
  harrisons_chapter:
  - classification_value: ENVIRONMENTAL_EXPOSURES
    evidence:
    - reference: PMID:7093149
      reference_title: "Evaluation of respiratory effects in miners and millers exposed to talc free of asbestos and silica."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Miners and millers of talc ore, free from asbestos and silica, were examined for respiratory effects."
      explanation: Identifies the disorder as an occupational inhalational exposure disease, supporting the primary Harrison's home in Occupational and Environmental Lung Disease.
  - classification_value: RESPIRATORY
    evidence:
    - reference: PMID:39030439
      reference_title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "A special form of silicatosis is talc pneumoconiosis or talcosis."
      explanation: Supports a secondary respiratory classification by placing the disease within the silicate pneumoconioses.
definitions:
- name: Clinical and pathological case definition for talc pneumoconiosis
  definition_type: CASE_DEFINITION
  description: >-
    Talc pneumoconiosis is a silicatosis: a dust disease of the lung following
    deposition of respirable talc, defined by a documented exposure together with
    the characteristic pathology of dust-laden macrophages, birefringent
    particles, foreign-body giant cells and centrilobular interstitial fibrosis.
  scope: Disease-level framing within the silicate pneumoconioses
  evidence:
  - reference: PMID:39030439
    reference_title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Silicatosis is a lung condition caused by inhalation of silicates, which comprises silicates such as talc, mica, and kaolinite"
    explanation: Places talc among the silicates whose inhalation causes silicatosis, which is the disease family this entry sits in.
  - reference: PMID:39030439
    reference_title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "At histology, focal peribronchial and perivascular fibrosis is associated with abundant dust deposits containing needle-shaped bluish-gray birefringent particles associated with giant cell response"
    explanation: States the defining histological combination of birefringent dust deposits, giant cell reaction and focal fibrosis.
- name: Histopathological diagnostic criteria for talc pneumoconiosis
  definition_type: DIAGNOSTIC_CRITERIA
  description: >-
    Diagnosis rests on polarized light microscopy demonstrating birefringent
    silicate crystals within centrilobular fibrotic areas, together with the
    stellate pattern of centrilobular interstitial fibrosis described as a
    medusa head. Morphology alone does not identify the mineral, so exposure
    history and mineral analysis remain necessary.
  scope: Pathological recognition and the limits of morphology alone
  evidence:
  - reference: PMID:39030439
    reference_title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Polarized light microscopy: birefringent crystals (silicates) in the centrilobular fibrotic brown areas of silicatosis."
    explanation: States the specific polarized-light finding used diagnostically.
  - reference: PMID:34401315
    reference_title: "Pulmonary talcosis in the setting of cosmetic talcum powder use."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Biopsy samples revealed abundant macrophages with white crystals that were negatively birefringent under polarized light indicative of talc crystals"
    explanation: A worked application of the same technique, here establishing the diagnosis after an inhalational cosmetic exposure.
  - reference: PMID:39030439
    reference_title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The typical features comprise patchy and stellate-shaped centrilobular interstitial fibrosis (so-called \"medusa head\") composed of a mixture of fibroblasts, collagen fibres, and dust-filled macrophages."
    explanation: States the characteristic stellate centrilobular fibrosis pattern and its cellular composition.
parents:
- pneumoconiosis
has_subtypes:
- name: Inhalational Talcosis
  display_name: Inhalational talcosis (occupational or cosmetic dust exposure)
  description: >-
    The pneumoconiosis proper. Respirable talc dust inhaled during mining,
    milling, bagging and manufacture, or during heavy cosmetic powder use,
    deposits in distal airways and the interstitium and produces centrilobular
    granulomas with stellate interstitial fibrosis. Mortality from pneumoconiosis
    is markedly raised in talc-industry cohorts.
  evidence:
  - reference: PMID:32816595
    reference_title: "Inhalation Toxicity of Talc."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The industrial mining, milling, and processing of talc ore is associated with elevated incidences of fibrotic and neoplastic diseases, which are also seen among workers exposed to RTP in secondary industries and individuals using processed cosmetic talc for personal use."
    explanation: Supports both the occupational and the cosmetic inhalational routes belonging to this subtype.
  - reference: PMID:36287869
    reference_title: "Risk of Mortality from Respiratory Malignant and Non-Malignant Diseases among Talc Miners and Millers: A Systematic Review and Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There was increased mortality for pneumoconiosis, especially in the miner's group (SMR = 7.90, CI 95% 2.77-22.58) and especially in those exposed to higher quartz concentration"
    explanation: Quantifies the pneumoconiosis mortality excess in occupationally exposed cohorts, and records that it was greatest where quartz co-exposure was higher.
- name: Intravascular Talcosis
  display_name: Intravascular talcosis (injected tablet excipients)
  description: >-
    An anatomically distinct disease reached by a different route. Crushed oral
    tablets injected intravenously deliver talc together with other insoluble
    excipients into the pulmonary vasculature, where they embolize and provoke
    perivascular foreign-body granulomas. Granulomas sit close to the pulmonary
    vessels rather than in the centrilobular interstitium, and the disease can
    progress to pulmonary arterial hypertension.
  evidence:
  - reference: PMID:40881529
    reference_title: "Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pulmonary talcosis is a rare granulomatous lung disease resulting from the intravenous injection of crushed oral tablets containing insoluble excipients such as talc, microcrystalline cellulose, and crospovidone."
    explanation: Defines this subtype by its exposure route and records that the injected material is a mixture of excipients rather than talc alone.
  - reference: PMID:39030439
    reference_title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "talc is a frequent filler in medications used for oral consumption or may reach the lungs by the vascular route in drug abusers (intravenous injection of crushed tablets; in this case the talc granulomas are localized close to the pulmonary vasculature)"
    explanation: States the anatomical distinction that separates this subtype from the inhalational form, with granulomas localized to the pulmonary vasculature.
progression:
- phase: Variable latency from exposure to symptoms
  notes: >-
    The interval between exposure and symptoms is not fixed. Reported cases span
    months to four decades, so a remote exposure does not exclude the diagnosis
    and a recent one does not date the disease.
  evidence:
  - reference: PMID:34401315
    reference_title: "Pulmonary talcosis in the setting of cosmetic talcum powder use."
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: "Among documented cases, there have been patients who manifested symptoms only months after exposure, as well as those who became symptomatic up to four decades after exposure"
    explanation: >-
      States the latency range across the reported literature. quote_role
      BACKGROUND because it summarizes other authors' cases rather than this one;
      those cases are human, which is what evidence_source grades.
- phase: Particle retention with radiographic opacities
  notes: >-
    The earliest recognized stage is retained dust with small round or irregular
    radiographic opacities, which can be present in workers who have never
    smoked and before symptoms dominate.
  evidence:
  - reference: PMID:7093149
    reference_title: "Evaluation of respiratory effects in miners and millers exposed to talc free of asbestos and silica."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 12 subjects whose chest radiographs showed small round or irregular opacities (perfusion 1/0 or greater), five had never smoked cigarettes."
    explanation: Supports an early radiographic stage, and establishes it in never-smokers so that smoking does not explain it away.
- phase: Accelerated loss of lung function
  notes: >-
    Function declines faster than predicted, and the excess persists after
    adjusting for cigarette smoking, which is what identifies the dust exposure
    rather than tobacco as the driver.
  evidence:
  - reference: PMID:7093149
    reference_title: "Evaluation of respiratory effects in miners and millers exposed to talc free of asbestos and silica."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pulmonary function values at the time of the initial study were less than predicted and the rates of loss of FEV1 and FVC greater than expected."
    explanation: Supports progressive functional decline measured over follow-up in an exposed cohort.
  - reference: PMID:7093149
    reference_title: "Evaluation of respiratory effects in miners and millers exposed to talc free of asbestos and silica."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There was evidence of an exposure effect after adjusting for cigarette smoking and we conclude that these workers have been affected by their exposures."
    explanation: Supports attribution of the decline to the dust exposure rather than to smoking.
- phase: Variable course after exposure ends in the intravascular form
  notes: >-
    One reported intravascular case was followed for three years with clinical
    stability and no disease-specific treatment, so established disease is not
    invariably progressive. That is a single case, and it is not the usual
    account: the review of this presentation states that most patients decline.
    Both are recorded here rather than one standing for the course.
  evidence:
  - reference: PMID:28538785
    reference_title: "Pulmonary talcosis caused by intravenous methadone injection."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "During 3 years of follow-up, the patient showed clinical stability with the persistence of dyspnea on exertion and dry cough."
    explanation: Documents three years of clinical stability, with persistent symptoms, in one intravascular case.
  - reference: PMID:40881529
    reference_title: "Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "It is important to note that most patients have a poor prognosis due to the progressive decline in pulmonary function."
    explanation: >-
      Counterweight to the phase as stated. If most patients decline
      progressively, a stable three-year course is not the typical outcome, and
      this phase should be read as one documented possibility.
pathophysiology:
- name: Respirable talc deposition in the distal lung
  description: >-
    Inhaled respirable talc deposits in the distal airways and the
    alveolar-interstitial compartment. The inhaled material is not pure: a
    substantial fraction behaves as fibres rather than compact particles, and
    commercial talc ore carries accessory minerals including tremolite,
    anthophyllite and quartz.
  biological_scale: ORGANISM
  locations:
  - preferred_term: lung
    term:
      id: UBERON:0002048
      label: lung
  - preferred_term: terminal bronchiole
    term:
      id: UBERON:0002187
      label: terminal bronchiole
  chemical_entities:
  - preferred_term: talc
    term:
      id: CHEBI:32178
      label: Talc
  biological_processes:
  - preferred_term: response to toxic substance
    modifier: INCREASED
    term:
      id: GO:0009636
      label: response to toxic substance
  evidence:
  - reference: PMID:32816595
    reference_title: "Inhalation Toxicity of Talc."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Respirable talc powder (RTP) is a complex mineral mixture of talc along with accessory minerals, including tremolite, anthophyllite, quartz, magnesite, dolomite, antigorite, lizardite, and chlorite."
    explanation: Establishes that the deposited material is a mineral mixture, which is what makes the attribution of downstream injury to talc alone difficult.
  - reference: PMID:32498698
    reference_title: "Analysis of particles from hamster lungs following pulmonary talc exposures: implications for pathogenicity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "fibers with aspect ratios 3:1 accounted for 22% of instilled material, mostly as fibrous talc"
    explanation: Quantifies the fibrous fraction of the instilled talc, which is the dimensional property relevant to deposition and clearance.
  downstream:
  - target: Alveolar macrophage uptake with impaired clearance
    causal_link_type: DIRECT
    description: Deposited particles are phagocytosed by alveolar macrophages, but cleared poorly.
    evidence:
    - reference: PMID:32498698
      reference_title: "Analysis of particles from hamster lungs following pulmonary talc exposures: implications for pathogenicity."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Phagocytosis of talc fibers by macrophages was observed"
      explanation: Supports the step from deposition to macrophage uptake, measured directly in talc-exposed animals.
- name: Alveolar macrophage uptake with impaired clearance
  description: >-
    Alveolar macrophages phagocytose talc particles, but clearance falls away
    over time: in hamsters, initial uptake of talc was high yet by two weeks
    phagocytosis by lavaged cells was significantly lower than for granite dust.
    Particles end up not only in macrophages but in neutrophils and
    multinucleate giant cells.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: alveolar macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: macrophage activation
    modifier: INCREASED
    term:
      id: GO:0042116
      label: macrophage activation
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:32498698
    reference_title: "Analysis of particles from hamster lungs following pulmonary talc exposures: implications for pathogenicity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "over the 14-day experiment, talc phagocytosis by lavaged cells was significantly less than that of granite"
    explanation: Directly supports failing particle clearance over two weeks, which is what allows retention rather than resolution.
  - reference: PMID:32498698
    reference_title: "Analysis of particles from hamster lungs following pulmonary talc exposures: implications for pathogenicity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "birefringent particles were found in macrophages, neutrophils, and multinucleate giant cells in lavaged cells from talc-exposed animals"
    explanation: Supports particle handling by three cell populations, including the giant cells that define the next step.
  - reference: PMID:32498698
    reference_title: "Analysis of particles from hamster lungs following pulmonary talc exposures: implications for pathogenicity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "BAL cell counts confirmed the presence of acute inflammation, which followed intratracheal instillation."
    explanation: >-
      The measured inflammatory response behind this node's macrophage
      activation and inflammatory response terms, which no other snippet here
      states.
  - reference: PMID:27446215
    reference_title: "Pulmonary Talcosis in an Immunocompromised Patient."
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: "After inhalational exposure, some talc particles are cleared by the tracheobronchial tree. However, if cleared insufficiently due to prolonged exposure or exposure to high quantities or both, pulmonary talcosis may develop."
    explanation: >-
      States the clearance-failure step in humans, which the hamster data measure
      but cannot establish for human lungs. quote_role BACKGROUND because the
      sentence restates established physiology rather than this paper's own case
      result; evidence_source grades the human clearance it describes.
  notes: >-
    Measured in hamsters after a single intratracheal instillation followed for
    14 days. Instillation is not inhalation and the follow-up is short, so the
    human long-term kinetics are inferred rather than demonstrated.
  downstream:
  - target: Foreign-body giant cell granuloma formation
    causal_link_type: DIRECT
    description: Poorly cleared particles drive a multinucleate foreign-body giant cell reaction.
    evidence:
    - reference: PMID:32498698
      reference_title: "Analysis of particles from hamster lungs following pulmonary talc exposures: implications for pathogenicity."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "birefringent particles were found in macrophages, neutrophils, and multinucleate giant cells in lavaged cells from talc-exposed animals"
      explanation: Supports the step to multinucleate giant cells containing the retained particles.
- name: Foreign-body giant cell granuloma formation
  description: >-
    Retained birefringent particles sit within granulomas formed by
    multinucleated foreign-body giant cells. On biopsy these appear as giant cell
    granulomas containing birefringent material, and under polarized light the
    crystals are visible inside the fibrotic areas.
  biological_scale: TISSUE
  locations:
  - preferred_term: lung
    term:
      id: UBERON:0002048
      label: lung
  cell_types:
  - preferred_term: multinucleated giant cell
    term:
      id: CL:0000647
      label: multinucleated giant cell
  biological_processes:
  - preferred_term: granuloma formation
    modifier: INCREASED
    term:
      id: GO:0002432
      label: granuloma formation
  evidence:
  - reference: PMID:39030439
    reference_title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "At histology, focal peribronchial and perivascular fibrosis is associated with abundant dust deposits containing needle-shaped bluish-gray birefringent particles associated with giant cell response"
    explanation: Supports the giant cell response accompanying the dust deposits as the characteristic histology.
  - reference: PMID:27446215
    reference_title: "Pulmonary Talcosis in an Immunocompromised Patient."
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: "Inhalational talc has been associated with histological patterns of diffuse interstitial fibrosis, nodular fibrosis, and foreign body granulomatosis"
    explanation: >-
      Names foreign-body granulomatosis as a histological pattern of inhalational
      talc specifically, which is the route this branch models.
  - reference: PMID:34401315
    reference_title: "Pulmonary talcosis in the setting of cosmetic talcum powder use."
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: "Once in the lungs, talc can cause non-necrotizing granulomas to form"
    explanation: States granuloma formation as the consequence of talc reaching the lung, for the inhalational route.
  - reference: PMID:32498698
    reference_title: "Analysis of particles from hamster lungs following pulmonary talc exposures: implications for pathogenicity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "birefringent particles were found in macrophages, neutrophils, and multinucleate giant cells in lavaged cells from talc-exposed animals"
    explanation: >-
      Giant cells containing birefringent talc after airway talc exposure, which
      is the inhalational counterpart of the human biopsy picture. Kept in place
      of the intravenous biopsy evidence that previously sat on this node, since
      this branch models the occupational disease.
  downstream:
  - target: Stellate centrilobular interstitial fibrosis
    causal_link_type: DIRECT
    description: Persistent granulomatous inflammation organizes into centrilobular interstitial fibrosis.
    evidence:
    - reference: PMID:39030439
      reference_title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The typical features comprise patchy and stellate-shaped centrilobular interstitial fibrosis (so-called \"medusa head\") composed of a mixture of fibroblasts, collagen fibres, and dust-filled macrophages."
      explanation: States the fibrotic lesion that contains the dust-filled macrophages, linking the granulomatous reaction to the fibrosis.
    - reference: PMID:34401315
      reference_title: "Pulmonary talcosis in the setting of cosmetic talcum powder use."
      supports: SUPPORT
      quote_role: BACKGROUND
      evidence_source: HUMAN_CLINICAL
      snippet: "The resulting chronic inflammation causes fibrosis, and potentially restrictive pulmonary disease and pulmonary hypertension in later phases."
      explanation: >-
        States the granulomatous-inflammation-to-fibrosis step directly, for the
        inhalational route, which no other item on this edge did.
    - reference: PMID:27446215
      reference_title: "Pulmonary Talcosis in an Immunocompromised Patient."
      supports: SUPPORT
      quote_role: BACKGROUND
      evidence_source: HUMAN_CLINICAL
      snippet: "Talc particles cause disease by being entrapped in the pulmonary parenchyma or vasculature causing a granulomatous reaction resulting in fibrotic lesions"
      explanation: States the same step and, usefully, states it for both the parenchymal and the vascular route in one sentence.
  - target: Granulomatosis
    causal_link_type: DIRECT
    description: The granulomatous reaction is itself the clinically and radiologically recognized lesion.
    evidence:
    - reference: PMID:39030439
      reference_title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "At histology, focal peribronchial and perivascular fibrosis is associated with abundant dust deposits containing needle-shaped bluish-gray birefringent particles associated with giant cell response"
      explanation: >-
        The giant cell reaction around the dust deposits is the granulomatous
        lesion this edge names, stated for the occupational disease rather than
        for an injection case.
- name: Stellate centrilobular interstitial fibrosis
  description: >-
    Fibroblasts and collagen accumulate around the retained dust, producing the
    patchy stellate centrilobular interstitial fibrosis that defines the
    silicatoses. Focal peribronchial and perivascular fibrosis accompanies it.
  biological_scale: TISSUE
  locations:
  - preferred_term: lung connective tissue
    term:
      id: UBERON:0000114
      label: lung connective tissue
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: collagen fibril organization
    modifier: INCREASED
    term:
      id: GO:0030199
      label: collagen fibril organization
  - preferred_term: extracellular matrix organization
    modifier: INCREASED
    term:
      id: GO:0030198
      label: extracellular matrix organization
  evidence:
  - reference: PMID:39030439
    reference_title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Silicatosis or other rare forms of dust: stellate-shaped centrilobular interstitial fibrosis composed of a mixture of fibroblasts, collagen fibres, and dust-filled macrophages."
    explanation: Directly supports the fibrotic lesion and names its fibroblast and collagen composition.
  downstream:
  - target: Pulmonary fibrosis
    causal_link_type: DIRECT
    description: The lesion presents clinically and radiologically as pulmonary fibrosis.
    evidence:
    - reference: PMID:39030439
      reference_title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "focal peribronchial and perivascular fibrosis is associated with abundant dust deposits"
      explanation: Supports established fibrosis as the tissue outcome of the dust deposition.
  - target: Small rounded and irregular radiographic opacities
    causal_link_type: DIRECT
    description: The fibrotic lesion and its retained dust are what the radiograph shows as small irregular opacities.
    evidence:
    - reference: PMID:39030439
      reference_title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Clinical and functional features are similar to silicosis, whereas the radiographic opacities are more irregular."
      explanation: States the radiographic expression of the talcotic lesion, and its irregular character.
  - target: Dyspnea
    causal_link_type: DIRECT
    description: Fibrosis impairs ventilation and gas transfer, producing breathlessness.
    evidence:
    - reference: PMID:39030439
      reference_title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: OTHER
      snippet: "Symptoms exhibited by affected individuals are often nonspecific, such as cough or shortness of breath, mimicking other respiratory conditions and complicating the diagnosis."
      explanation: >-
        Graded INDIRECT because the source states breathlessness as the
        presentation of occupational lung disease as a class rather than
        measuring it against this entry's fibrotic lesion. It replaces an
        intravenous case report, which should not carry an edge in the
        inhalational chain.
  - target: Cough
    causal_link_type: DIRECT
    description: The fibrotic and granulomatous lesion provokes the chronic cough patients present with.
    evidence:
    - reference: PMID:34401315
      reference_title: "Pulmonary talcosis in the setting of cosmetic talcum powder use."
      supports: SUPPORT
      directness: INDIRECT
      quote_role: BACKGROUND
      evidence_source: HUMAN_CLINICAL
      snippet: "the presenting symptoms of pulmonary talcosis are nonspecific and include dyspnea on exertion, cough, weight loss, anorexia, and diaphoresis"
      explanation: >-
        Graded INDIRECT because the source lists cough as a presenting symptom of
        the disease rather than tying it to this lesion by measurement.
  - target: Reduced forced expiratory volume in one second
    causal_link_type: DIRECT
    description: Fibrosis and airway damage reduce measured expiratory flow over time.
    evidence:
    - reference: PMID:7093149
      reference_title: "Evaluation of respiratory effects in miners and millers exposed to talc free of asbestos and silica."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Pulmonary function values at the time of the initial study were less than predicted and the rates of loss of FEV1 and FVC greater than expected."
      explanation: Supports accelerated decline in measured expiratory volume in exposed workers.
- name: Intravascular excipient embolization
  description: >-
    The alternative route. Crushed oral tablets injected intravenously deliver
    talc together with microcrystalline cellulose and crospovidone into the
    pulmonary circulation, where the insoluble particles embolize in arterioles
    and capillaries. Because the injected material is a mixture, a birefringent
    particle on biopsy does not establish that the agent was talc.
  biological_scale: ORGANISM
  locations:
  - preferred_term: pulmonary artery
    term:
      id: UBERON:0002012
      label: pulmonary artery
  chemical_entities:
  - preferred_term: talc
    term:
      id: CHEBI:32178
      label: Talc
  biological_processes:
  - preferred_term: response to toxic substance
    modifier: INCREASED
    term:
      id: GO:0009636
      label: response to toxic substance
  evidence:
  - reference: PMID:40881529
    reference_title: "Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These substances embolize within the pulmonary vasculature, provoking granulomatous inflammation that may progress to pulmonary arterial hypertension (PAH)."
    explanation: Directly supports embolization of the injected excipients within the pulmonary vasculature as the initiating step of this branch.
  downstream:
  - target: Perivascular foreign-body granulomatosis
    causal_link_type: DIRECT
    description: Embolized particles provoke granulomatous inflammation around the pulmonary vessels.
    evidence:
    - reference: PMID:28538785
      reference_title: "Pulmonary talcosis caused by intravenous methadone injection."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The centrilobular nodules were determined histopathologically to be tiny foreign body particles lodged in the centrilobular arterioles and perivascular space."
      explanation: Human histopathology locating the particles in the centrilobular arterioles and perivascular space, which is the step this edge asserts.
- name: Perivascular foreign-body granulomatosis
  description: >-
    Granulomas form around and within the pulmonary arterioles rather than in the
    centrilobular interstitium, which is the anatomical signature separating this
    branch from the inhalational disease. Radiologically this appears as
    centrilobular nodules that spare the subpleural regions and fissures.
  biological_scale: TISSUE
  locations:
  - preferred_term: pulmonary artery
    term:
      id: UBERON:0002012
      label: pulmonary artery
  cell_types:
  - preferred_term: multinucleated giant cell
    term:
      id: CL:0000647
      label: multinucleated giant cell
  biological_processes:
  - preferred_term: granuloma formation
    modifier: INCREASED
    term:
      id: GO:0002432
      label: granuloma formation
  evidence:
  - reference: PMID:39030439
    reference_title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "in this case the talc granulomas are localized close to the pulmonary vasculature"
    explanation: Directly supports the perivascular localization that distinguishes this branch anatomically.
  - reference: PMID:28538785
    reference_title: "Pulmonary talcosis caused by intravenous methadone injection."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The centrilobular nodules were determined histopathologically to be tiny foreign body particles lodged in the centrilobular arterioles and perivascular space."
    explanation: Human histopathology of the perivascular and intra-arteriolar particle location.
  downstream:
  - target: Pulmonary arterial hypertension
    causal_link_type: DIRECT
    description: Granulomatous involvement of the pulmonary arterioles raises pulmonary vascular resistance.
    evidence:
    - reference: PMID:40881529
      reference_title: "Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These substances embolize within the pulmonary vasculature, provoking granulomatous inflammation that may progress to pulmonary arterial hypertension (PAH)."
      explanation: The quoted sentence states the progression from perivascular granulomatous inflammation to pulmonary arterial hypertension.
  - target: Centrilobular nodules on computed tomography
    causal_link_type: DIRECT
    description: The particles lodged in the centrilobular arterioles and perivascular space are what computed tomography resolves as centrilobular nodules.
    evidence:
    - reference: PMID:28538785
      reference_title: "Pulmonary talcosis caused by intravenous methadone injection."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The centrilobular nodules were determined histopathologically to be tiny foreign body particles lodged in the centrilobular arterioles and perivascular space."
      explanation: Establishes the histological basis of the nodules seen on imaging.
  - target: Granulomatosis
    causal_link_type: DIRECT
    description: The perivascular granulomas are the recognized lesion of this branch.
    evidence:
    - reference: PMID:40881529
      reference_title: "Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Pulmonary talcosis is a rare granulomatous lung disease resulting from the intravenous injection of crushed oral tablets"
      explanation: Supports the disease of this branch being a granulomatous lung disease.
phenotypes:
- name: Dyspnea
  category: Respiratory
  description: >-
    Progressive breathlessness is the usual presenting symptom in both routes,
    reflecting impaired ventilation and gas transfer.
  phenotype_term:
    preferred_term: Dyspnea
    term:
      id: HP:0002094
      label: Dyspnea
  evidence:
  - reference: PMID:28538785
    reference_title: "Pulmonary talcosis caused by intravenous methadone injection."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A 38-year-old woman presented to our pulmonology clinic with complaints of progressive dyspnea and dry cough for more than three months."
    explanation: Documents progressive dyspnea as the presenting complaint in a confirmed case.
  - reference: PMID:34401315
    reference_title: "Pulmonary talcosis in the setting of cosmetic talcum powder use."
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: "the presenting symptoms of pulmonary talcosis are nonspecific and include dyspnea on exertion, cough, weight loss, anorexia, and diaphoresis"
    explanation: >-
      Names dyspnea as a presenting symptom of the disease generally, including
      the inhalational route, so this phenotype does not rest on an injection
      case alone.
- name: Cough
  category: Respiratory
  description: >-
    Dry cough accompanies the breathlessness.
  phenotype_term:
    preferred_term: Cough
    term:
      id: HP:0012735
      label: Cough
  evidence:
  - reference: PMID:28538785
    reference_title: "Pulmonary talcosis caused by intravenous methadone injection."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "complaints of progressive dyspnea and dry cough for more than three months"
    explanation: Documents dry cough alongside dyspnea in a confirmed case.
  - reference: PMID:34401315
    reference_title: "Pulmonary talcosis in the setting of cosmetic talcum powder use."
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: "the presenting symptoms of pulmonary talcosis are nonspecific and include dyspnea on exertion, cough, weight loss, anorexia, and diaphoresis"
    explanation: Names cough among the presenting symptoms of the disease generally, not only of the injection form.
- name: Pulmonary fibrosis
  category: Respiratory
  description: >-
    Interstitial fibrosis in a stellate centrilobular distribution, with focal
    peribronchial and perivascular involvement, is the defining structural lesion
    of the inhalational form. It is left unscoped because the intravascular route
    is also reported to produce interstitial fibrosis, although the stellate
    centrilobular pattern is described for the inhalational disease.
  phenotype_term:
    preferred_term: Pulmonary fibrosis
    term:
      id: HP:0002206
      label: Pulmonary fibrosis
  evidence:
  - reference: PMID:39030439
    reference_title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Silicatosis or other rare forms of dust: stellate-shaped centrilobular interstitial fibrosis composed of a mixture of fibroblasts, collagen fibres, and dust-filled macrophages."
    explanation: Supports interstitial fibrosis as the characteristic lesion of the silicatoses including talcosis.
  - reference: PMID:40881529
    reference_title: "Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "this process can result in PAH and interstitial fibrosis"
    explanation: Supports interstitial fibrosis as an outcome of the intravascular route too, which is why this phenotype is not scoped to the inhalational subtype.
  - reference: PMID:28538785
    reference_title: "Pulmonary talcosis caused by intravenous methadone injection."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Over time, talc micronodules may coalesce into perihilar conglomerate masses, resembling progressive massive fibrosis from silicosis or coal workers' pneumoconiosis."
    explanation: Supports coalescence of the nodular lesions into conglomerate masses, the advanced form of the fibrotic phenotype.
  - reference: PMID:27446215
    reference_title: "Pulmonary Talcosis in an Immunocompromised Patient."
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: "Inhalational talc has been associated with histological patterns of diffuse interstitial fibrosis, nodular fibrosis, and foreign body granulomatosis"
    explanation: Names the fibrotic patterns of the inhalational route specifically, which this phenotype now covers for both routes.
- name: Granulomatosis
  category: Respiratory
  description: >-
    Foreign-body granulomas containing birefringent particles are present in both
    routes, differing in location: centrilobular and interstitial after
    inhalation, perivascular after injection.
  phenotype_term:
    preferred_term: Granulomatosis
    term:
      id: HP:0002955
      label: Granulomatosis
  evidence:
  - reference: PMID:28538785
    reference_title: "Pulmonary talcosis caused by intravenous methadone injection."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Transbronchial biopsy performed in the left lower lobe showed multinucleated giant cell granulomas with birefringent foreign material, compatible with talc"
    explanation: Human biopsy confirmation of giant cell granulomas with birefringent material.
- name: Lower lobe panacinar emphysema
  category: Respiratory
  subtype: Intravascular Talcosis
  description: >-
    Advanced intravascular talcosis is reported with panacinar, lower
    lobe-predominant emphysema on high-resolution computed tomography. No
    mechanism for it is established here, so it carries no incoming causal edge.
  phenotype_term:
    preferred_term: lower lobe panacinar emphysema
    term:
      id: HP:0032967
      label: Panacinar emphysema
  evidence:
  - reference: PMID:40881529
    reference_title: "Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "high-resolution computed tomography (HRCT) can demonstrate nodular opacities, diffuse ground-glass patterns, and lower lobe-predominant panacinar emphysema"
    explanation: States lower lobe-predominant panacinar emphysema among the imaging findings of this presentation.
  - reference: PMID:40881529
    reference_title: "Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In advanced cases, manifestations may include cor pulmonale, panlobular emphysema"
    explanation: Supports emphysema as a manifestation of advanced disease, under its panlobular synonym.
- name: Pulmonary arterial hypertension
  category: Cardiovascular
  description: >-
    Granulomatous involvement of the pulmonary arterioles can raise pulmonary
    arterial pressure, with right ventricular strain and elevated right
    ventricular pressures on imaging. It is best documented in the intravascular
    form, where the lesion sits on the vasculature, but it is also reported in
    advanced inhalational disease, so the phenotype is not scoped to one subtype.
  phenotype_term:
    preferred_term: Pulmonary arterial hypertension
    term:
      id: HP:0002092
      label: Pulmonary arterial hypertension
  evidence:
  - reference: PMID:40881529
    reference_title: "Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These substances embolize within the pulmonary vasculature, provoking granulomatous inflammation that may progress to pulmonary arterial hypertension (PAH)."
    explanation: Supports pulmonary arterial hypertension as a documented consequence of the intravascular form.
  - reference: PMID:40881529
    reference_title: "Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Imaging revealed elevated right ventricular pressures and computed tomography (CT) findings of centrilobular nodules with sparing of the subpleural regions and fissures, characteristic of talc granulomatosis."
    explanation: Documents the measured right ventricular pressure elevation in a confirmed case.
  - reference: PMID:27446215
    reference_title: "Pulmonary Talcosis in an Immunocompromised Patient."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "consistent with severe pulmonary hypertension"
    explanation: >-
      Severe pulmonary hypertension on echocardiography in a patient whose talc
      exposure was inhaled cosmetic powder rather than injection. Read with its
      confounders: this man was 82 with chronic obstructive pulmonary disease, 30
      pack-years and terminal leukaemia, and his talcosis was a clinical
      diagnosis because biopsy was not pursued, so his pulmonary hypertension has
      competing causes. The biopsy-confirmed case below is the stronger support
      for unscoping this phenotype.
  - reference: PMID:27446215
    reference_title: "Pulmonary Talcosis in an Immunocompromised Patient."
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: "In another reported case in 1977, a ten-year-old child, who had accidentally inhaled a large quantity of baby talcum powder once at the age of two, was diagnosed with pulmonary fibrosis with evidence of pulmonary hypertension and biopsy evidence of pulmonary talcosis"
    explanation: >-
      Biopsy-confirmed talcosis with pulmonary hypertension after a single
      inhalational exposure, and no injection, which is the cleanest support for
      this phenotype occurring by the inhalational route.
  - reference: PMID:34401315
    reference_title: "Pulmonary talcosis in the setting of cosmetic talcum powder use."
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: "The resulting chronic inflammation causes fibrosis, and potentially restrictive pulmonary disease and pulmonary hypertension in later phases."
    explanation: Names pulmonary hypertension as a late consequence of the inhalational route as well.
- name: Reduced forced expiratory volume in one second
  category: Laboratory
  subtype: Inhalational Talcosis
  description: >-
    Expiratory volume and vital capacity decline faster than predicted in exposed
    workers, and the excess decline persists after adjustment for smoking.
  phenotype_term:
    preferred_term: Reduced forced expiratory volume in one second
    term:
      id: HP:0032342
      label: Reduced forced expiratory volume in one second
  evidence:
  - reference: PMID:7093149
    reference_title: "Evaluation of respiratory effects in miners and millers exposed to talc free of asbestos and silica."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pulmonary function values at the time of the initial study were less than predicted and the rates of loss of FEV1 and FVC greater than expected."
    explanation: Supports reduced and declining expiratory volume in a cohort exposed to talc free of asbestos and silica.
- name: Small rounded and irregular radiographic opacities
  category: Respiratory
  description: >-
    Small round or irregular opacities on the chest radiograph are the imaging
    expression of retained dust and the granulomatous reaction to it. In talcosis
    the opacities are more irregular than the rounded opacities of silicosis.
  phenotype_term:
    preferred_term: small rounded and irregular radiographic opacities
    term:
      id: HP:0002207
      label: Diffuse reticular or finely nodular infiltrations
  evidence:
  - reference: PMID:7093149
    reference_title: "Evaluation of respiratory effects in miners and millers exposed to talc free of asbestos and silica."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 12 subjects whose chest radiographs showed small round or irregular opacities (perfusion 1/0 or greater), five had never smoked cigarettes."
    explanation: Supports radiographic opacities in exposed workers, including never-smokers.
  - reference: PMID:39030439
    reference_title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Clinical and functional features are similar to silicosis, whereas the radiographic opacities are more irregular."
    explanation: Supports the irregular character of the opacities, which is what distinguishes them radiographically from silicosis.
- name: Centrilobular nodules on computed tomography
  category: Respiratory
  description: >-
    Both routes produce centrilobular nodules, and the distribution differs. In
    the intravascular form they spare the subpleural regions and the fissures, a
    pattern the reporting authors treat as characteristic of talc
    granulomatosis; after inhalation they are typically middle- or upper-lobe
    predominant with ground-glass opacity. The phenotype is left unscoped for
    that reason, with the route-specific distributions in the evidence.
  phenotype_term:
    preferred_term: centrilobular nodules on computed tomography
    term:
      id: HP:0025392
      label: Nodular pattern on pulmonary HRCT
  evidence:
  - reference: PMID:40881529
    reference_title: "Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Imaging revealed elevated right ventricular pressures and computed tomography (CT) findings of centrilobular nodules with sparing of the subpleural regions and fissures, characteristic of talc granulomatosis."
    explanation: States the computed tomography pattern and its distribution in an intravascular case.
  - reference: PMID:28538785
    reference_title: "Pulmonary talcosis caused by intravenous methadone injection."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The centrilobular nodules were determined histopathologically to be tiny foreign body particles lodged in the centrilobular arterioles and perivascular space."
    explanation: Ties the nodules seen on imaging to the particles lodged in the centrilobular arterioles.
  - reference: PMID:34401315
    reference_title: "Pulmonary talcosis in the setting of cosmetic talcum powder use."
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: "Chest CT in patients who inhale talc is typically characterized by middle- or upper-lobe predominant centrilobular nodules and ground glass opacities"
    explanation: States the inhalational distribution, which is why this phenotype is no longer scoped to the intravascular subtype.
  - reference: PMID:34401315
    reference_title: "Pulmonary talcosis in the setting of cosmetic talcum powder use."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CT chest demonstrated bilateral centrilobular nodules, now with upper lobe predominance without hilar adenopathy along with a left sided pleural effusion"
    explanation: The imaging in the cosmetic-powder case, a worked instance of the inhalational distribution.
environmental:
- name: Non-occupational inhalation of cosmetic and household talcum powder
  description: >-
    Talc in cosmetic face powder, body powder and baby powder is inhaled during
    application. Two reported cases reached pulmonary talcosis this way: a woman
    who applied talcum face powder excessively for two years, and a man who
    deliberately inhaled scented talcum powder over years. This route is
    inhalational, so it belongs to the same subtype as the occupational dust, but
    it reaches people with no industrial history at all, which is why both cases
    were first misdiagnosed. The first was confirmed on transbronchial biopsy;
    the second was a clinical and radiological diagnosis, biopsy having been ruled
    out by thrombocytopenia, so it is the weaker of the two.
  exposure_term:
    preferred_term: exposure to talc dust
    term:
      id: ECTO:7000028
      label: exposure to talc dust
  effect: Deposits respirable talc in the distal lung outside any occupational setting.
  evidence:
  - reference: PMID:34401315
    reference_title: "Pulmonary talcosis in the setting of cosmetic talcum powder use."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the patient admitted to excessive application of talcum face powder for two years prior to her presentation"
    explanation: The exposure history that established the diagnosis in a woman with no occupational or injection exposure.
  - reference: PMID:27446215
    reference_title: "Pulmonary Talcosis in an Immunocompromised Patient."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "he would often inhale lavender-scented talcum powder for relaxation during his business trips for an unspecified number of years"
    explanation: A second non-occupational inhalational exposure, here deliberate inhalation rather than cosmetic application.
  - reference: PMID:34401315
    reference_title: "Pulmonary talcosis in the setting of cosmetic talcum powder use."
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: OTHER
    snippet: "talc exposure from household products is often overlooked as a causative agent of inhalation pneumoconiosis"
    explanation: >-
      States why this route matters clinically. Kept at OTHER because the
      sentence is the authors' judgement about clinical attention rather than a
      description of evidence, with quote_role BACKGROUND because it is framing
      rather than their own case finding.
  - reference: PMID:27446215
    reference_title: "Pulmonary Talcosis in an Immunocompromised Patient."
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: "Pulmonary talcosis is most commonly seen secondary to occupational exposure or intravenous (IV) drug abuse and, occasionally, in excessive use of cosmetic talc."
    explanation: Places this route in proportion against the two principal ones, which is the honest reading.
  influences_mechanisms:
  - target: Respirable talc deposition in the distal lung
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: Inhalation during cosmetic application or deliberate use delivers respirable talc to the distal lung.
    evidence:
    - reference: PMID:34401315
      reference_title: "Pulmonary talcosis in the setting of cosmetic talcum powder use."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Biopsy samples revealed abundant macrophages with white crystals that were negatively birefringent under polarized light indicative of talc crystals"
      explanation: Confirms talc actually reached and was retained in the distal lung by this route, on biopsy.
  notes: >-
    Neither source claims cosmetic talc is hazardous in ordinary use. The second
    states plainly that there is no substantial evidence that cosmetic talc
    presents a health hazard when used as intended; both reported cases involved
    heavy or deliberate inhalation. The entry records the route without asserting
    a risk at normal use.
- name: Ambient fibrous talc in non-occupationally exposed lungs
  description: >-
    Fibrous talc is recoverable from the lungs of Japanese women with no
    occupational exposure. The reported comparison is narrower than it first
    looks: fibrous talc counts were higher in urban lung cancer cases than in
    urban non-cancer, rural cancer and rural non-cancer cases, so the contrast is
    cancer-stratified and is not a general urban-versus-rural one. The study did
    not assess talcosis.
  exposure_term:
    preferred_term: exposure to talc dust
    term:
      id: ECTO:7000028
      label: exposure to talc dust
  environment_context:
    preferred_term: urban biome
    term:
      id: ENVO:01000249
      label: urban biome
  effect: >-
    Fibrous talc is present in the lungs of people with no occupational exposure.
    The source of that talc is not established by the study.
  evidence:
  - reference: PMID:9222135
    reference_title: "Talc and amosite/crocidolite preferentially deposited in the lungs of nonoccupational female lung cancer cases in urban areas of Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Amosite/crocidolite and fibrous talc counts in urban lung cancer cases were greater than those of urban non-lung cancer cases, rural lung cancer, and rural non-lung cancer cases"
    explanation: >-
      Measures fibrous talc in lung tissue from women without occupational
      exposure. Note what the comparison is: urban lung cancer cases against the
      other three groups. It does not compare urban non-cancer with rural cases,
      so it does not establish a general urban excess, and it does not identify
      ambient air as the source of the talc.
  - reference: PMID:9222135
    reference_title: "Talc and amosite/crocidolite preferentially deposited in the lungs of nonoccupational female lung cancer cases in urban areas of Japan."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: "fibrous talc in urban environments may be another candidate for carcinogenic or cocarcinogenic factors of female lung cancer"
    explanation: >-
      Recorded as NO_EVIDENCE for this entry's claims. The authors raise ambient
      fibrous talc as a candidate lung-cancer factor; that is a hypothesis about
      a different disease, and this entry neither asserts nor relies on it.
  notes: >-
    Deliberately carries no influences_mechanisms link, so it does not appear in
    the pathograph. The only claim the source supports is that fibrous talc is
    found in some lungs without occupational exposure. It is a case-control count
    of lung fibres: it does not show that ambient air was the route, and it says
    nothing about this disease, so an edge into the deposition node would add a
    claim rather than evidence. The entry is kept as context for non-occupational
    exposure, alongside the cosmetic-powder route, which does have case-level
    evidence for its route.
- name: Occupational inhalation of respirable talc dust
  description: >-
    Mining, crushing, milling, bagging and manufacture of talc-containing
    products generate respirable talc dust. Pneumoconiosis mortality is markedly
    raised in these cohorts, most of all among miners and in cohorts with higher
    quartz content.
  exposure_term:
    preferred_term: exposure to talc dust
    term:
      id: ECTO:7000028
      label: exposure to talc dust
    qualifiers:
    - predicate:
        preferred_term: has input
        term:
          id: RO:0002233
          label: has input
      value:
        preferred_term: talc
        term:
          id: CHEBI:32178
          label: Talc
  environment_context:
    preferred_term: factory
    term:
      id: ENVO:01000536
      label: factory
  effect: Deposits respirable talc, with its accessory minerals, in the distal lung over years of work.
  evidence:
  - reference: PMID:32816595
    reference_title: "Inhalation Toxicity of Talc."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The industrial mining, milling, and processing of talc ore is associated with elevated incidences of fibrotic and neoplastic diseases, which are also seen among workers exposed to RTP in secondary industries and individuals using processed cosmetic talc for personal use."
    explanation: Supports industrial talc processing as the principal occupational exposure route.
  - reference: PMID:36287869
    reference_title: "Risk of Mortality from Respiratory Malignant and Non-Malignant Diseases among Talc Miners and Millers: A Systematic Review and Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There was increased mortality for pneumoconiosis, especially in the miner's group (SMR = 7.90, CI 95% 2.77-22.58) and especially in those exposed to higher quartz concentration"
    explanation: Quantifies the mortality consequence of this exposure, and records the quartz-dependence that complicates attributing it to talc.
  influences_mechanisms:
  - target: Respirable talc deposition in the distal lung
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: Occupational dust generation delivers respirable talc to the distal lung.
    evidence:
    - reference: PMID:7093149
      reference_title: "Evaluation of respiratory effects in miners and millers exposed to talc free of asbestos and silica."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "There was evidence of an exposure effect after adjusting for cigarette smoking and we conclude that these workers have been affected by their exposures."
      explanation: Supports the occupational exposure itself producing respiratory effect, in a cohort where asbestos and silica were absent from the ore.
- name: Intravenous injection of crushed oral tablets
  description: >-
    Injection of crushed tablets intended for oral use delivers talc filler, with
    other insoluble excipients, directly into the venous circulation and so into
    the pulmonary arterioles. This is not an occupational pneumoconiosis and its
    pathology is perivascular rather than centrilobular.
  exposure_term:
    preferred_term: exposure to talc
    term:
      id: ECTO:9000055
      label: exposure to talc
    qualifiers:
    - predicate:
        preferred_term: has input
        term:
          id: RO:0002233
          label: has input
      value:
        preferred_term: talc
        term:
          id: CHEBI:32178
          label: Talc
  effect: Delivers insoluble tablet excipients, talc among them, into the pulmonary vasculature.
  evidence:
  - reference: PMID:40881529
    reference_title: "Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pulmonary talcosis is a rare granulomatous lung disease resulting from the intravenous injection of crushed oral tablets containing insoluble excipients such as talc, microcrystalline cellulose, and crospovidone."
    explanation: Supports injection of crushed oral tablets as the exposure route for this branch, and names the excipient mixture delivered.
  - reference: PMID:39030439
    reference_title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "talc is a frequent filler in medications used for oral consumption or may reach the lungs by the vascular route in drug abusers (intravenous injection of crushed tablets; in this case the talc granulomas are localized close to the pulmonary vasculature)"
    explanation: Supports the vascular delivery route and its distinct perivascular pathology.
  influences_mechanisms:
  - target: Intravascular excipient embolization
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: Injection places insoluble particles in the venous return, which carries them to the pulmonary arterioles.
    evidence:
    - reference: PMID:40881529
      reference_title: "Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These substances embolize within the pulmonary vasculature, provoking granulomatous inflammation that may progress to pulmonary arterial hypertension (PAH)."
      explanation: Supports the exposure initiating embolization within the pulmonary vasculature.
animal_models:
- name: Hamster intratracheal talc instillation model
  species: Hamster
  publication: PMID:32498698
  description: >-
    Male hamsters given a single intratracheal instillation of talc and followed
    for 14 days, with bronchoalveolar lavage cells examined by polarized light
    microscopy. The instilled material was characterized by scanning electron
    microscopy with energy-dispersive x-ray analysis, and asbestos and quartz
    were below detection, which is what makes this a talc-attributable
    observation rather than a mixed-mineral one.
  modeled_mechanisms:
  - target: Alveolar macrophage uptake with impaired clearance
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Reproduces macrophage phagocytosis of talc and the subsequent decline in
      clearance, with particles appearing in macrophages, neutrophils and giant
      cells.
    limitations: >-
      Intratracheal instillation is a bolus delivery that does not reproduce
      aerosol deposition during chronic occupational inhalation, the follow-up is
      only 14 days against a human disease of years, only male animals were used,
      and hamster particle clearance differs from human.
    readouts:
    - name: Phagocytosis of birefringent talc particles by lavaged cells
      target: Alveolar macrophage uptake with impaired clearance
      direction: DECREASED
      interpretation: Falling particle uptake over 14 days, the clearance failure this node asserts.
      evidence:
      - reference: PMID:32498698
        reference_title: "Analysis of particles from hamster lungs following pulmonary talc exposures: implications for pathogenicity."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "over the 14-day experiment, talc phagocytosis by lavaged cells was significantly less than that of granite"
        explanation: Reports the measured decline in talc phagocytosis relative to a comparator dust.
    evidence:
    - reference: PMID:32498698
      reference_title: "Analysis of particles from hamster lungs following pulmonary talc exposures: implications for pathogenicity."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Phagocytosis of talc fibers by macrophages was observed"
      explanation: Supports treating this model as informative for the macrophage uptake node.
  evidence:
  - reference: PMID:32498698
    reference_title: "Analysis of particles from hamster lungs following pulmonary talc exposures: implications for pathogenicity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "birefringent particles were found in macrophages, neutrophils, and multinucleate giant cells in lavaged cells from talc-exposed animals"
    explanation: Characterizes the cellular distribution of retained particles in this model.
treatments:
- name: Cessation of talc exposure
  description: >-
    Removing the exposure is the only intervention that acts on the cause. No
    treatment reverses established fibrosis, and spontaneous resolution of
    established fibrosis is not established, so prevention of further deposition
    is the actionable step. Cessation is not a cure: established disease is
    reported to progress even after every exposure has stopped.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: talc dust exposure avoidance
    term:
      id: NCIT:C15900
      label: Lifestyle Therapy
    qualifiers:
    - predicate:
        preferred_term: has input
        term:
          id: RO:0002233
          label: has input
      value:
        preferred_term: talc
        term:
          id: CHEBI:32178
          label: Talc
  target_mechanisms:
  - target: Respirable talc deposition in the distal lung
    treatment_effect: INHIBITS
    description: Ending the exposure prevents further deposition and retention of dust.
    evidence:
    - reference: PMID:7093149
      reference_title: "Evaluation of respiratory effects in miners and millers exposed to talc free of asbestos and silica."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "Populations such as this will need to be studied for longer periods to determine what current dust levels are safe."
      explanation: >-
        Graded INDIRECT because the source argues for dust-level control as the
        unresolved preventive question rather than measuring the effect of
        cessation on an individual's disease.
  evidence:
  - reference: PMID:28538785
    reference_title: "Pulmonary talcosis caused by intravenous methadone injection."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients must stop exposure and all tobacco use."
    explanation: >-
      States the cessation recommendation directly. Note the source is an
      intravenous case report, so the explicit recommendation in the literature
      comes from the injection setting; the occupational arm of this treatment
      rests on the dust-level evidence cited on the mechanism link.
  - reference: PMID:40881529
    reference_title: "Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Management primarily involves supportive care and cessation of intravenous drug use."
    explanation: States cessation of the exposure as the mainstay of management, again from the intravenous literature.
  - reference: PMID:34401315
    reference_title: "Pulmonary talcosis in the setting of cosmetic talcum powder use."
    supports: REFUTE
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: "There is no specific treatment. The disease may continue to progress even if all talc exposures have ceased"
    explanation: >-
      Counterweight to reading cessation as disease-modifying. Progression after
      complete cessation is reported, so this treatment prevents further
      deposition rather than arresting the disease.
- name: Supportive management of established disease
  description: >-
    Management of established talcosis is supportive, directed at symptoms,
    oxygenation and any pulmonary hypertension rather than at the retained dust.
    In the reported intravascular case, oxygen, antiplatelet therapy and oral
    sildenafil improved symptoms.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_mechanisms:
  - target: Pulmonary arterial hypertension
    treatment_effect: MODULATES
    description: Pulmonary vasodilator therapy addresses the raised pulmonary arterial pressure rather than the granulomas causing it.
    evidence:
    - reference: PMID:40881529
      reference_title: "Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Pulmonary hypertension associated with this condition may be managed with vasodilators; in some cases, oral sildenafil has shown promise."
      explanation: >-
        States vasodilator therapy as the management of the pulmonary
        hypertension of this condition, which supports the edge more directly
        than one patient's regimen does.
  evidence:
  - reference: PMID:40881529
    reference_title: "Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient was managed with supplemental oxygen, antiplatelet therapy, and oral sildenafil, resulting in symptomatic improvement"
    explanation: Supports supportive and vasodilator management as the reported approach in established disease.
- name: Lung transplantation for end-stage disease
  description: >-
    Where disease is end-stage and unresponsive to medical therapy, lung
    transplantation is reported as an option. It does not act on the retained
    dust or the granulomatous reaction; it replaces the organ they have damaged.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: lung transplantation
    term:
      id: NCIT:C15289
      label: Organ Transplantation
  target_mechanisms:
  - target: Stellate centrilobular interstitial fibrosis
    treatment_effect: BYPASSES
    description: Replacing the lung bypasses the fibrotic lesion rather than reversing it.
    evidence:
    - reference: PMID:40881529
      reference_title: "Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "Lung transplantation may be considered in patients with end-stage disease unresponsive to medical therapy"
      explanation: >-
        Graded INDIRECT because the source states transplantation as an option in
        end-stage disease without reporting an outcome against the fibrotic
        lesion itself.
  evidence:
  - reference: PMID:28538785
    reference_title: "Pulmonary talcosis caused by intravenous methadone injection."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lung transplantation is considered to be a viable option for the treatment of talcosis."
    explanation: States transplantation as a treatment option for talcosis.
differential_diagnoses:
- name: Silicosis
  distinguishing_features:
  - Both are mineral dust pneumoconioses and talc ore frequently carries quartz, so the two can coexist in one patient
  - Talcosis shows needle-shaped bluish-gray birefringent particles with a giant cell response
  - Where crystalline silica is a substantial accompaniment the disease is termed talcosilicosis rather than talcosis
  evidence:
  - reference: PMID:39030439
    reference_title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "At histology, focal peribronchial and perivascular fibrosis is associated with abundant dust deposits containing needle-shaped bluish-gray birefringent particles associated with giant cell response"
    explanation: Supports the particle morphology and giant cell reaction that identify talc rather than silica on biopsy.
  - reference: PMID:36287869
    reference_title: "Risk of Mortality from Respiratory Malignant and Non-Malignant Diseases among Talc Miners and Millers: A Systematic Review and Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "especially in those exposed to higher quartz concentration"
    explanation: Supports quartz co-exposure as a real and quantitatively important confounder, which is why these two diseases have to be distinguished deliberately.
discussions:
- discussion_id: talc-vs-contaminant-attribution
  kind: CONTROVERSY
  status: OPEN
  prompt: >-
    Is the fibrosis of occupational talc pneumoconiosis caused by talc itself, or
    by the quartz and amphibole minerals that accompany commercial talc ore?
  rationale: >-
    The question is not settled and it bears directly on every causal edge in the
    inhalational branch of this entry. Commercial respirable talc is a mineral
    mixture that can include tremolite, anthophyllite and quartz, and the
    pneumoconiosis mortality excess in talc-industry cohorts was highest where
    quartz content was higher, which is what a contaminant effect would look
    like. Against a pure-contaminant explanation, the Vermont cohort was
    explicitly exposed to ore free of asbestos and silica and still showed
    radiographic opacities in never-smokers and an exposure effect on lung
    function after adjusting for smoking; and the hamster instillation study
    characterized its material with asbestos and quartz below detection. The
    entry therefore asserts a talc-attributable mechanism, while recording that
    the magnitude of the occupational disease burden cannot be attributed to talc
    alone from the available cohorts.
  attaches_to:
  - pathophysiology#Respirable talc deposition in the distal lung
  - pathophysiology#Stellate centrilobular interstitial fibrosis
  evidence:
  - reference: PMID:32816595
    reference_title: "Inhalation Toxicity of Talc."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "There is controversial evidence of a link between the talc-induced lung diseases and a potential contamination with asbestos fibers."
    explanation: States that the contamination link is itself controversial, which is the controversy this discussion records.
  - reference: PMID:32816595
    reference_title: "Inhalation Toxicity of Talc."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This controversy is fueled by inadequate exposure data and the complex mineralogy and terminology of the accessory minerals."
    explanation: Names the reasons the question remains open, namely exposure data quality and mineralogical complexity.
  - reference: PMID:7093149
    reference_title: "Evaluation of respiratory effects in miners and millers exposed to talc free of asbestos and silica."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There was evidence of an exposure effect after adjusting for cigarette smoking and we conclude that these workers have been affected by their exposures."
    explanation: The strongest evidence on the talc-attributable side, from a cohort whose ore was free of asbestos and silica.
notes: >-
  Two routes, two diseases, one identifier. The entry is split into inhalational
  and intravascular subtypes because the anatomy differs rather than merely the
  exposure: inhaled talc produces centrilobular and interstitial granulomas with
  stellate fibrosis, while injected tablet excipients produce granulomas close to
  the pulmonary vasculature and can raise pulmonary arterial pressure. Findings
  from intravenous cases should not be transferred to the occupational disease,
  and the entry keeps their evidence separate: no edge or node in the inhalational
  chain is supported by an injection case. The separation applies to the
  mechanism chains. Clinical features that occur by both routes, such as
  breathlessness, cough and granulomatous histology, are curated as shared
  phenotypes and may carry evidence from either literature; where a feature is
  reported for one route only it is scoped with `subtype:`.

  The intravascular branch is not a talc-only disease even when talc is present.
  Crushed tablets deliver microcrystalline cellulose and crospovidone alongside
  talc, so a birefringent particle on biopsy does not establish which excipient
  caused the lesion. The entry names the mixture rather than attributing the
  granulomas to talc alone.

  No frequency bands are assigned to phenotypes. The quantitative human data are
  cohort counts and pooled standardized mortality ratios rather than
  phenotype frequencies among affected individuals: 12 of 116 workers with
  radiographic opacities is a cohort count in one mine, and the pneumoconiosis
  SMR is a mortality ratio, not a proportion of patients with a feature. A
  FrequencyEnum band derived from either would misreport what was measured.

  No genetic section. No causal gene, susceptibility locus or inherited enzyme
  defect is established for this disease; it is defined entirely by exposure.

  Signalling pathways are deliberately not asserted. The deep-research report
  for this entry was explicit that TNF, IL-1-beta/NLRP3, MAPK, PI3K-AKT, mTOR,
  Wnt and TGF-beta contributions in human talc pneumoconiosis are inferred from
  other pneumoconioses rather than demonstrated, and that findings from silicosis
  or from pleural talc instillation must not be imported as though confirmed in
  inhalational talcosis. One in-vitro study does implicate PI3K in talc-induced
  cell death and IL-6 secretion, but it used lung carcinoma cells in the context
  of pleurodesis, so it is not cited here as a mechanism of this disease.

  Three exposure routes, two subtypes. The subtypes divide the disease by how
  talc reaches the lung, inhaled or injected, because that is what sets the
  anatomy. Non-occupational inhalation of cosmetic or household powder is a third
  route and a real one, with two reported cases here, but it is inhalational and
  produces the same lesion, so it is curated as an environmental entry under the
  inhalational subtype rather than as a third subtype. Ambient urban exposure is
  recorded the same way, as a route by which talc reaches the lung.

  What the non-occupational sources are not claiming. Neither case report says
  cosmetic talc is hazardous in ordinary use, and one states the opposite
  explicitly; both patients had heavy or deliberate inhalation. The urban
  lung-burden study measured fibrous talc in lung tissue and raised it as a
  candidate factor in lung cancer, which is a hypothesis about a different
  disease: that item is graded NO_EVIDENCE here, and this entry asserts nothing
  about talc and lung cancer.

  The attribution question is recorded as a CONTROVERSY discussion rather than
  resolved. See that entry for the evidence on both sides.
references:
- reference: PMID:34401315
  title: "Pulmonary talcosis in the setting of cosmetic talcum powder use."
- reference: PMID:27446215
  title: "Pulmonary Talcosis in an Immunocompromised Patient."
- reference: PMID:9222135
  title: "Talc and amosite/crocidolite preferentially deposited in the lungs of nonoccupational female lung cancer cases in urban areas of Japan."
- reference: PMID:39030439
  title: "The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group."
- reference: PMID:32816595
  title: "Inhalation Toxicity of Talc."
- reference: PMID:36287869
  title: "Risk of Mortality from Respiratory Malignant and Non-Malignant Diseases among Talc Miners and Millers: A Systematic Review and Meta-Analysis."
- reference: PMID:32498698
  title: "Analysis of particles from hamster lungs following pulmonary talc exposures: implications for pathogenicity."
- reference: PMID:40881529
  title: "Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case."
- reference: PMID:28538785
  title: "Pulmonary talcosis caused by intravenous methadone injection."
- reference: PMID:7093149
  title: "Evaluation of respiratory effects in miners and millers exposed to talc free of asbestos and silica."

📚

References & Deep Research

References

10

PMID:34401315

Pulmonary talcosis in the setting of cosmetic talcum powder use.

No top-level findings curated for this source.

PMID:27446215

Pulmonary Talcosis in an Immunocompromised Patient.

No top-level findings curated for this source.

PMID:9222135

Talc and amosite/crocidolite preferentially deposited in the lungs of nonoccupational female lung cancer cases in urban areas of Japan.

No top-level findings curated for this source.

PMID:39030439

The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group.

No top-level findings curated for this source.

PMID:32816595

Inhalation Toxicity of Talc.

No top-level findings curated for this source.

PMID:36287869

Risk of Mortality from Respiratory Malignant and Non-Malignant Diseases among Talc Miners and Millers: A Systematic Review and Meta-Analysis.

No top-level findings curated for this source.

PMID:32498698

Analysis of particles from hamster lungs following pulmonary talc exposures: implications for pathogenicity.

No top-level findings curated for this source.

PMID:40881529

Pulmonary Arterial Hypertension Due to Talc Granulomatosis Following Intravenous Use of Oral Medications: A Report of a Rare Case.

No top-level findings curated for this source.

PMID:28538785

Pulmonary talcosis caused by intravenous methadone injection.

No top-level findings curated for this source.

PMID:7093149

Evaluation of respiratory effects in miners and millers exposed to talc free of asbestos and silica.

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (2)

Record notes

Two routes, two diseases, one identifier. The entry is split into inhalational and intravascular subtypes because the anatomy differs rather than merely the exposure: inhaled talc produces centrilobular and interstitial granulomas with stellate fibrosis, while injected tablet excipients produce granulomas close to the pulmonary vasculature and can raise pulmonary arterial pressure. Findings from intravenous cases should not be transferred to the occupational disease, and the entry keeps their evidence separate: no edge or node in the inhalational chain is supported by an injection case. The separation applies to the mechanism chains. Clinical features that occur by both routes, such as breathlessness, cough and granulomatous histology, are curated as shared phenotypes and may carry evidence from either literature; where a feature is reported for one route only it is scoped with `subtype:`. The intravascular branch is not a talc-only disease even when talc is present. Crushed tablets deliver microcrystalline cellulose and crospovidone alongside talc, so a birefringent particle on biopsy does not establish which excipient caused the lesion. The entry names the mixture rather than attributing the granulomas to talc alone. No frequency bands are assigned to phenotypes. The quantitative human data are cohort counts and pooled standardized mortality ratios rather than phenotype frequencies among affected individuals: 12 of 116 workers with radiographic opacities is a cohort count in one mine, and the pneumoconiosis SMR is a mortality ratio, not a proportion of patients with a feature. A FrequencyEnum band derived from either would misreport what was measured. No genetic section. No causal gene, susceptibility locus or inherited enzyme defect is established for this disease; it is defined entirely by exposure. Signalling pathways are deliberately not asserted. The deep-research report for this entry was explicit that TNF, IL-1-beta/NLRP3, MAPK, PI3K-AKT, mTOR, Wnt and TGF-beta contributions in human talc pneumoconiosis are inferred from other pneumoconioses rather than demonstrated, and that findings from silicosis or from pleural talc instillation must not be imported as though confirmed in inhalational talcosis. One in-vitro study does implicate PI3K in talc-induced cell death and IL-6 secretion, but it used lung carcinoma cells in the context of pleurodesis, so it is not cited here as a mechanism of this disease. Three exposure routes, two subtypes. The subtypes divide the disease by how talc reaches the lung, inhaled or injected, because that is what sets the anatomy. Non-occupational inhalation of cosmetic or household powder is a third route and a real one, with two reported cases here, but it is inhalational and produces the same lesion, so it is curated as an environmental entry under the inhalational subtype rather than as a third subtype. Ambient urban exposure is recorded the same way, as a route by which talc reaches the lung. What the non-occupational sources are not claiming. Neither case report says cosmetic talc is hazardous in ordinary use, and one states the opposite explicitly; both patients had heavy or deliberate inhalation. The urban lung-burden study measured fibrous talc in lung tissue and raised it as a candidate factor in lung cancer, which is a hypothesis about a different disease: that item is graded NO_EVIDENCE here, and this entry asserts nothing about talc and lung cancer. The attribution question is recorded as a CONTROVERSY discussion rather than resolved. See that entry for the evidence on both sides.

Create: Talc Pneumoconiosis · 2026-10-07T17:50:11Z · View source

New Disease entry for pneumoconiosis due to talc (MONDO:0001003), curated as two has_subtypes because the two exposure routes produce anatomically distinct disease: Inhalational Talcosis (occupational or heavy cosmetic dust, centrilobular and interstitial granulomas with stellate fibrosis) and Intravascular Talcosis (injected crushed-tablet excipients, perivascular granulomas progressing to pulmonary arterial hypertension). Deep research: Edison Falcon (research/Talc_Pneumoconiosis-deep-research-falcon.md, 11/11 references verified, confabulation_rate 0.0). needs_review was set for one off-topic reference and a label variant, neither a content defect. The report was unusually disciplined and shaped three decisions in this entry: it insisted that findings from intravenous cases must not be assigned to inhalational disease, it flagged the quartz/asbestos contamination attribution problem, and it warned explicitly that TNF, IL-1-beta/NLRP3, MAPK, PI3K-AKT, mTOR, Wnt and TGF-beta contributions in human talc pneumoconiosis are inferred from other pneumoconioses rather than demonstrated, and that silicosis or pleural-instillation findings must not be imported. All three warnings were acted on. The report was used as a lead set only; every citation was re-fetched and snippet-verified and every CURIE was looked up in OAK while writing. Pathograph: 6 nodes in two branches, each rooted at its own environmental exposure link, no orphans. Inhalational: respirable talc deposition -> alveolar macrophage uptake with impaired clearance -> foreign-body giant cell granuloma formation -> stellate centrilobular interstitial fibrosis -> dyspnea, pulmonary fibrosis, reduced FEV1. Intravascular: excipient embolization -> perivascular foreign-body granulomatosis -> pulmonary arterial hypertension. The central curation problem is attribution, and it is recorded as a CONTROVERSY discussion rather than resolved. Commercial respirable talc is a mineral mixture including tremolite, anthophyllite and quartz, and the pneumoconiosis mortality excess was highest where quartz content was higher (SMR 7.90 in miners), which is what a contaminant effect would look like. Against a pure-contaminant reading, the Wegman Vermont cohort was exposed to ore explicitly free of asbestos and silica and still showed radiographic opacities in never-smokers plus an exposure effect on lung function after smoking adjustment, and the hamster instillation study characterized its material with asbestos and quartz below detection. The entry therefore asserts a talc-attributable mechanism while recording that the occupational disease burden cannot be attributed to talc alone from the available cohorts. The discussion attaches to the deposition and fibrosis nodes. Other deliberate decisions, recorded in notes: (1) No FrequencyEnum bands on any phenotype; the quantitative human data are cohort counts (12 of 116 workers with opacities in one mine) and pooled standardized mortality ratios, neither of which is a phenotype frequency among affected individuals. (2) No genetic section; the disease is defined entirely by exposure. (3) No signalling pathway asserted, per the report's warning. The one in-vitro PI3K study is deliberately not cited as a mechanism of this disease because it used lung carcinoma cells in a pleurodesis context. (4) The intravascular branch is described as an excipient mixture rather than talc alone, since crushed tablets also deliver microcrystalline cellulose and crospovidone and a birefringent particle does not identify which one caused the lesion. (5) Two edges carry directness: INDIRECT where the source argues a preventive point rather than measuring an effect. animal_models carries the hamster intratracheal instillation model wired to the macrophage-clearance node with a phagocytosis readout, and limitations recording that instillation is not inhalation, the follow-up was 14 days against a human disease of years, only male animals were used, and hamster clearance differs from human. One error caught during curation: the reference_title for PMID:36287869 had 'of Cohort Studies' appended, which is not in the real title. A scripted audit of every reference_title against its own cache file caught it across 4 occurrences; it was replaced from the cache by script, and a re-run reports 7/7 titles matching. Validation run and read: just validate-disorders (60 snippets, 67 titles, 0 issues), just validate-terms (passed), just count-verified-snippets (60/60), just check-entity-refs (OK), just check-causal-targets (no new broken targets), just check-duplicate-keys (OK), just check-qualifier-terms (3 labels match cache). New terms were seeded by pointing conf/oak_config.yaml at local sqlite adapters for the validator run and then restoring it; conf/ is unmodified in the diff.

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 46 citations 2026-10-07T13:37:37.377058

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Talc Pneumoconiosis
MONDO ID: MONDO:0001003 (if available)
Category: Environmental

Research Objectives

Please provide a comprehensive research report on Talc Pneumoconiosis covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Present this section as an ordered causal chain first, then the detail below. Open with a numbered sequence of mechanistic steps running from the initiating lesion (mutation, exposure, infection) to the clinical manifestation, one step per line, each naming what it causes next. State the causal verb explicitly ("leads to", "results in") and say where a step is inferred rather than demonstrated. Where the mechanism branches, show the branch. The categories below are a checklist of what to cover within those steps, not the organizing structure — a step may draw on several of them, and a category may contribute to several steps.

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Talc pneumoconiosis: disease-characteristics research report

Scope and evidence standard. Talc pneumoconiosis is the inhalational, usually occupational, form of pulmonary talcosis. Intravenous injection of talc-containing crushed tablets causes a related but anatomically distinct pulmonary foreign-body/excipient granulomatosis; findings from intravenous cases must not be assigned automatically to inhalational disease. Likewise, quartz- or asbestos-contaminated talc can produce mixed-mineral disease rather than an effect attributable to talc alone. This report distinguishes original human observations, animal experiments, expert reviews, and untested extrapolations. (calabrese2024theroleof pages 3-5, antao2006lungdiseasesassociated pages 11-12, lassandro2024noninfectiousgranulomatouslung pages 11-14)

The following evidence matrix identifies the most informative quantitative and pathology sources before the detailed characteristics.

Study/type	Exposed subjects/route	Validated observations	Key limitation	Source DOI/PMID
Wegman et al., 1982; primary occupational cohort	116 Vermont talc miners/millers exposed to ore reported free of silica and asbestos; inhalation	12/116 workers had radiographic small opacities; 103 were followed for 1 year; FEV₁ and FVC declined more than expected. These are cohort counts, not population prevalence estimates. (antao2006lungdiseasesassociated pages 11-12)	Numerical findings were recovered from the Antao review rather than directly from the original full text; smoking partly explained functional decline.	PMID: 7093149
Ciocan et al., 2022; systematic review/meta-analysis	Seven male mining/milling cohorts; n=5,394; occupational inhalation; 28–74 years of follow-up	Pneumoconiosis mortality: overall SMR 5.62 (95% CI 2.83–11.14), miners 7.90 (2.76–22.58), millers 2.64 (1.40–4.96), and cohorts with quartz >1% 9.55 (7.48–12.18). (ciocan2022riskofmortality pages 6-8, ciocan2022riskofmortality pages 1-2, ciocan2022riskofmortality pages 2-4)	The pooled category is pneumoconiosis among talc-industry workers, not proven talc-only pneumoconiosis; quartz/asbestos exposure varied, smoking data were incomplete, and only a few cohorts existed. (ciocan2022riskofmortality pages 2-4, ciocan2022riskofmortality pages 8-10)	DOI: 10.3390/toxics10100589
Escuissato et al., 2017; human case report	38-year-old woman; single intravenous injection of crushed methadone tablet	SpO₂ 92%; residual volume 127% predicted; DLCO 70% predicted; diffuse bilateral centrilobular/tree-in-bud nodules; biopsy showed giant-cell granulomas with birefringent material. Symptoms and CT remained stable over 3 years without disease-specific treatment. (escuissato2017pulmonarytalcosiscaused pages 1-2)	Single IV-excipient case—not occupational inhalational pneumoconiosis; crushed tablets may contain insoluble excipients other than talc.	DOI: 10.1590/S1806-37562016000000337
Sato et al., 2020; primary animal reanalysis	Male hamsters; single intratracheal talc instillation, followed for 14 days	Fibers with aspect ratio ≥3:1 constituted 22% of instilled material, mostly fibrous talc; asbestos and quartz were below detection. Talc particles occurred in macrophages, neutrophils, and multinucleated giant cells, supporting acute inflammation and impaired particle ingestion. (sato2020analysisofparticles pages 1-2, sato2020analysisofparticles pages 13-14)	Instillation does not reproduce chronic occupational inhalation or aerosol deposition; short follow-up, male-only animals, and hamster clearance differs from humans.	DOI: 10.1186/s12989-020-00356-0
Calabrese et al., 2024; European Society of Pathology expert opinion	Disease-level expert synthesis; occupational inhalation contrasted with vascular delivery after IV injection of crushed tablets	Inhaled silicates produce patchy/stellate centrilobular interstitial fibrosis with fibroblasts, collagen, and dust-laden macrophages; IV talc produces perivascular granulomas, focal perivascular/peribronchial fibrosis, birefringent particles, and foreign-body giant cells. (calabrese2024theroleof pages 3-5, calabrese2024theroleof pages 1-2)	Expert review rather than a talc-specific cohort; morphology overlaps sarcoidosis and other mineral-dust diseases, so exposure history and mineral analysis remain essential.	DOI: 10.1007/s00428-024-03845-1

Table: Compact evidence matrix distinguishing occupational talc pneumoconiosis from intravenous talc granulomatosis and experimental exposure. It emphasizes which quantitative findings are descriptive, pooled, or mechanistic and identifies major attribution limitations.

1. Disease information

Definition. Talc pneumoconiosis, also called inhalational talcosis, is a dust-related pulmonary disease following deposition of respirable talc—hydrated magnesium silicate, Mg₃Si₄O₁₀(OH)₂. Findings range from retained particles and small radiographic opacities to foreign-body granulomas, interstitial fibrosis, and occasionally confluent fibrotic masses. Commercial “talc” may be a mineral mixture rather than pure talc. Talcosilicosis denotes important accompanying crystalline silica; talcoasbestosis denotes an asbestos-associated pattern. “Intravascular talcosis” or “excipient lung disease” should be recorded separately by exposure route. (calabrese2024theroleof pages 3-5, antao2006lungdiseasesassociated pages 11-12, franquet2021noninfectiousgranulomatouslung pages 7-9, rosenman2012talc pages 1-2)

Identifiers and provenance. The supplied disease identifier is MONDO:0001003, but its current ontology mapping was not independently verified by the accessible sources. The retrieved trial registry identifies the parent concept Pneumoconiosis as MeSH D011009; this is not evidence for a talc-specific MeSH descriptor. Candidate ICD-10 classification is J62.0, pneumoconiosis due to talc dust, subject to verification against the relevant national ICD edition before database import. No independently verified disease-specific OMIM, Orphanet, or ICD-11 identifier was retrieved. This entry synthesizes published case descriptions, exposure cohorts, experiments, and disease-level expert interpretation; it is not an individual’s EHR record. (NCT05288179 chunk 1, calabrese2024theroleof pages 1-2, ciocan2022riskofmortality pages 2-4)

2. Etiology and risk or protective factors

The necessary initiating exposure is inhalation of respirable talc dust, encountered during mining, crushing, milling, bagging, loading, and manufacture or handling of talc-containing products; exceptional heavy cosmetic or deliberate inhalational exposures are described. Intensity, duration, respirable particle size, and mineral composition are relevant. Deposits can contain quartz, tremolite, anthophyllite, or other minerals; asbestos-related pleural changes and silica-like lesions should not be attributed to pure talc. Injection of crushed oral tablets is an alternative pulmonary exposure pathway, not occupational pneumoconiosis. (antao2006lungdiseasesassociated pages 11-12, sato2020analysisofparticles pages 1-2, ciocan2022riskofmortality pages 1-2, rosenman2012talc pages 1-2)

In an older study summarized by Antao and colleagues, 116 Vermont miners/millers handling ore described as free of silica and asbestos were evaluated: 12/116 (10.3%) had small radiographic opacities, and 103 were followed for one year. This is a study-group observation, not disease prevalence; smoking partly contributed to greater-than-expected FEV₁ and FVC declines. A separate French study of 166 millers associated greater exposure with dyspnea, small opacities, and lower FEV₁/FVC. In 108 Brazilian soapstone workers, whose dust also contained tremolite-actinolite fibers, 34% reported dyspnea, five had small opacities, and seven had abnormal spirometry: this cannot isolate talc’s effect. Original Vermont study: Wegman et al., August 1982, PMID 7093149, https://pubmed.ncbi.nlm.nih.gov/7093149/; these particular numerical observations were verified in a subsequent occupational-disease review, not independently re-extracted from that primary article. (antao2006lungdiseasesassociated pages 11-12)

Protective exposures: lowering airborne dust and eliminating avoidable quartz/asbestos co-exposure are the defensible interventions; cessation of smoking reduces a competing respiratory risk but has not been shown specifically to prevent talc pneumoconiosis. No established protective dietary factor or protective genetic allele was found. Gene–environment interaction: general mineral-dust susceptibility is biologically plausible, but no reproducible talc-specific susceptibility locus, gene–talc interaction, or family-history effect was established. The 2024 pathology opinion mentions GSTM1, GSTT1, and SOD2 as general occupational respiratory-disease candidates, not validated talc-pneumoconiosis genes. (calabrese2024theroleof pages 3-5, antao2006lungdiseasesassociated pages 11-12, calabrese2024theroleof pages 17-19)

3. Phenotypes and suggested HPO terms

The HPO labels below are candidates for ontology reconciliation, not validated frequency-coded talcosis annotations. Onset is generally in exposed adults and can be delayed for years; intensity and admixtures strongly affect presentation. Except where explicitly shown, disease-wide percentages, severity distributions, and phenotype-specific quality-of-life scores are unavailable. (antao2006lungdiseasesassociated pages 11-12, calabrese2024theroleof pages 1-2)

Phenotype and type	Character, onset/course, frequency and functional impact	Suggested HPO label
Exertional dyspnea; symptom	Variable, potentially progressive with fibrosis; limits walking/work. 34% in one asbestos-contaminated soapstone worker sample, not a talc-only estimate.	Dyspnea / exertional dyspnea
Cough, sometimes sputum; symptoms	May be absent for years or persist chronically; can disturb activity and sleep. Frequency unavailable.	Cough; productive cough
Bilateral small lung opacities; imaging sign	Can occur without symptoms; 12/116 in the older Vermont sample. Bilateral centrilobular/subpleural nodules are described in inhalational cases.	Abnormal pulmonary opacity; pulmonary nodule
Reduced FEV₁ or FVC; functional-test abnormality	Obstructive, restrictive, or mixed patterns; may worsen with continued exposure. No reliable talc-specific frequency.	Obstructive lung disease / restrictive ventilatory defect (verify exact HPO terms)
Reduced diffusing capacity, exertional hypoxemia; physiological abnormalities	Particularly relevant to extensive parenchymal injury; can limit exercise. The IV case had DLCO 70% predicted and room-air SpO₂ 92%, not representative of occupational frequency.	Reduced pulmonary diffusing capacity; hypoxemia
Foreign-body granulomas, interstitial fibrosis; tissue findings	Histological findings, ranging from limited to extensive; substantial fibrosis can impair gas exchange.	Pulmonary granuloma; pulmonary fibrosis
Crackles, clubbing, cyanosis, respiratory failure/cor pulmonale; clinical signs/complications	Mainly described in advanced or mixed/asbestosis-like disease; not universal or quantified.	Pulmonary crackles; clubbing; cyanosis; respiratory insufficiency; cor pulmonale

Clinical and functional assignments above derive from worker observations and talcosis descriptions; the quoted IV measurements are deliberately labeled as such. No talc-specific behavioral syndrome or validated blood/urine laboratory phenotype was identified. No talc-specific EQ-5D, SF-36, or PROMIS estimate was retrieved. (escuissato2017pulmonarytalcosiscaused pages 1-2, antao2006lungdiseasesassociated pages 11-12, rosenman2012talc pages 6-7)

4. Genetic and molecular information

No Mendelian causal gene, chromosomal alteration, pathogenic germline or somatic variant, ACMG/AMP classification, allele frequency, inheritance-linked modifier, or protective allele is established for this environmentally initiated condition. Consequently, OMIM gene IDs, HGNC disease-gene assignments, variant nomenclature, penetrance, carrier frequency, and founder variants should be marked not applicable/not established, rather than populated with genes involved in generic fibrosis. Likewise, no disease-specific validated DNA methylation, chromatin, or histone signature was found; the 2022 occupational meta-analysis explicitly describes talc-related epigenetic investigations as very limited. (calabrese2024theroleof pages 3-5, ciocan2022riskofmortality pages 8-10)

5. Environmental information

The relevant environmental entity is inhalable/respirable talc; record separately the composition of actual sampled ore or product, including crystalline silica and amphibole asbestos where present. Smoking can complicate respiratory symptoms, lung-function interpretation, and mortality comparisons, but should not be coded as a proven talc-specific causal exposure. Ordinary diet, alcohol, exercise, and radiation have no demonstrated primary etiological role. No bacterial, viral, fungal, or parasitic agent causes talc pneumoconiosis; infections are important differentials or complications, not its initiating lesion. Suggested ChEBI entities for checking against the live ontology are talc, silicon dioxide/quartz, and nicotine where documenting a competing exposure; do not assign an unverified ChEBI numeric identifier. (escuissato2017pulmonarytalcosiscaused pages 1-2, antao2006lungdiseasesassociated pages 11-12, ciocan2022riskofmortality pages 2-4, rosenman2012talc pages 1-2)

6. Mechanism and pathophysiology

Ordered causal chain — inhalational disease first; IV branch shown explicitly:

Repeated inhalation of respirable talc, sometimes mixed with quartz or asbestos, leads to particle deposition and retention in distal airways and alveolar/interstitial regions. Co-contaminants constitute a mechanistically separate branch. (calabrese2024theroleof pages 3-5, sato2020analysisofparticles pages 1-2, franquet2021noninfectiousgranulomatouslung pages 7-9)
Retained particles lead to uptake by alveolar macrophages and, experimentally, neutrophils; poorly cleared or larger particles lead to multinucleated foreign-body giant-cell reactions. The cell uptake and acute inflammation are directly demonstrated in talc-exposed hamsters; human long-term kinetics are inferred. (sato2020analysisofparticles pages 1-2, sato2020analysisofparticles pages 13-14)
Persistent particle-associated inflammation leads to macrophage-rich granulomas and cytokine/growth-factor signaling; the specific causal contributions of TNF, IL-1β/NLRP3, MAPK, PI3K–AKT, mTOR, Wnt, or TGF-β in human talc pneumoconiosis remain inferred from other pneumoconioses, not demonstrated here. Generic occupational-dust oxidative stress/ROS is plausible; it is not an established talc-specific clinical pathway. (calabrese2024theroleof pages 3-5, sato2020analysisofparticles pages 1-2, sato2020analysisofparticles pages 13-14)
Sustained inflammation and repair lead to fibroblast activity, collagen accumulation, peribronchiolar/centrilobular or interstitial scarring and, in some cases, conglomerate masses. Talc-associated fibrosis is observed histologically in humans; prolonged nonfibrous-talc inhalation experimentally produced collagen accumulation and fibrosis in rats, with a less fibrotic response in mice. (calabrese2024theroleof pages 3-5, rosenman2012talc pages 4-6, franquet2021noninfectiousgranulomatouslung pages 7-9)
Fibrosis and associated airway damage lead to impaired ventilation/gas transfer, dyspnea, cough and exercise limitation; extensive disease can lead to respiratory failure and secondary right-heart strain. The exact patient-to-patient causal rate is not established. (antao2006lungdiseasesassociated pages 11-12, rosenman2012talc pages 6-7, calabrese2024theroleof pages 17-19)
Alternative IV branch: injection of crushed tablets leads to excipient microemboli in pulmonary arterioles/capillaries leads to perivascular foreign-body granulomas and sometimes fibrosis/thrombosis can lead to pulmonary hypertension. Because tablets may contain cellulose, crospovidone, or starch, a birefringent particle alone does not prove chemically pure talc. (nagarajan2025pulmonaryarterialhypertension pages 2-4, escuissato2017pulmonarytalcosiscaused pages 1-2, lassandro2024noninfectiousgranulomatouslung pages 11-14)

Upstream versus downstream and annotations. Upstream events are exposure, deposition, clearance and inflammatory-cell recruitment; downstream events are collagen deposition, architectural damage, reduced DLCO, and cardiopulmonary manifestations. Candidate GO biological-process labels, requiring term-ID verification, are phagocytosis, response to inorganic substance, inflammatory response, granuloma formation, extracellular-matrix organization, and collagen fibril organization. Candidate Cell Ontology (CL) labels are alveolar macrophage, neutrophil, multinucleated giant cell, lung fibroblast, and, for IV injury, vascular endothelial cell. No specific dysfunctional host protein, inherited enzyme defect, altered metabolite/lipid signature, or validated talc-specific transcriptomic, proteomic, single-cell, spatial, multi-omics, or CRISPR-screen result was established by the retrieved evidence. It would be misleading to import findings from silicosis or pleural talc instillation as if experimentally confirmed in inhalational talcosis. (calabrese2024theroleof pages 3-5, sato2020analysisofparticles pages 1-2, rosenman2012talc pages 4-6)

7. Anatomical structures affected

Primary: both lungs, especially distal respiratory units—alveoli, alveolar septa/interstitium, centrilobular bronchiolar regions, and peribronchial connective tissue. IV-specific additional site: pulmonary arterioles and their perivascular/interstitial surroundings. Dust-laden macrophages and foreign-body giant cells occupy granulomas; fibroblasts and deposited collagen characterize scarring. Secondary: pulmonary vessels and right heart in advanced pulmonary hypertension/cor pulmonale; pleural plaques/thickening raise concern for associated asbestos, not necessarily talc alone. Candidate UBERON labels to map locally are lung, pulmonary alveolus, bronchiole, pulmonary artery, pleura, and heart; candidate GO cellular-component labels are phagosome/lysosome (particle handling) and extracellular matrix (fibrosis), with human-talcosis subcellular localization not specifically validated. Findings are often bilateral rather than characteristically unilateral. The 2024 Figure 7A CT image illustrates centrilobular micronodules in talc granulomatosis; it must not be read as evidence of an occupational route without an exposure history. (calabrese2024theroleof pages 3-5, antao2006lungdiseasesassociated pages 11-12, lassandro2024noninfectiousgranulomatouslung pages 11-14, lassandro2024noninfectiousgranulomatouslung media bed83719)

8. Temporal development

Occupational inhalation usually produces an insidious adult-onset process after sustained exposure, but radiological or symptomatic disease can be recognized years after a relatively short workplace exposure; there is no single defensible minimum latency. Conceptual—not formally validated—stages are particle retention/early small opacities → symptomatic or functionally impaired diffuse disease → confluent fibrosis and possible cardiopulmonary complications. Outcomes vary from persistent but stable abnormalities to progression; spontaneous disappearance of established fibrosis is not established. The IV route can instead begin after a discrete exposure: in the original 2017 case, injection occurred approximately one month before symptom onset, and symptoms and CT remained stable for three years without disease-specific medication. Prompt exposure reduction is the principal actionable window; no disease-specific developmental critical period or quantitative remission probability is available. (escuissato2017pulmonarytalcosiscaused pages 1-2, antao2006lungdiseasesassociated pages 11-12, rosenman2012talc pages 6-7, calabrese2024theroleof pages 1-2)

9. Inheritance, population and epidemiology

Inheritance: none defined; autosomal/X-linked/mitochondrial patterns, genetic anticipation, germline mosaicism, consanguinity, penetrance, carrier frequencies, and variant geography are not applicable absent an established causal allele. Talcosis tracks where dust-producing work or particular exposure practices occur, not a demonstrated ancestry-specific biological predisposition. The mining/milling meta-analysis included 5,394 men in seven cohorts across Italy, Norway, France, Austria, and the United States, followed for 28–74 years. This all-male cohort composition reflects recruitment and work patterns and cannot establish a biological male:female susceptibility ratio. No valid general-population talc-pneumoconiosis incidence per year or point prevalence per 100,000 was found. The 12/116 Vermont observation describes radiographic findings among exposed workers, not general-population disease prevalence. (antao2006lungdiseasesassociated pages 11-12, ciocan2022riskofmortality pages 2-4)

Quantitative mortality association, not incidence: pooled pneumoconiosis mortality SMR 5.62 (95% CI 2.83–11.14) in talc-industry cohorts; miners 7.90 (2.76–22.58) versus millers 2.64 (1.40–4.96). In cohorts grouped by quartz content, estimates were 9.55 (7.48–12.18) for >1% quartz and 5.82 (3.10–10.91) for <1%. These are deaths coded as pneumoconiosis in talc-exposed workplaces, not histologically confirmed pure-talc deaths; they should not be presented as population mortality rates. Ciocan et al., published 5 October 2022, https://doi.org/10.3390/toxics10100589. (ciocan2022riskofmortality pages 6-8, ciocan2022riskofmortality pages 1-2, ciocan2022riskofmortality pages 2-4)

10. Diagnostics

Practical clinical sequence: (a) obtain a dated job/product history, duration and intensity, other dusts, IV medication use, and smoking history; review industrial-hygiene measurements and mineral composition; (b) assess symptoms, oxygenation, spirometry/lung volumes, and DLCO; (c) obtain chest radiography, with ILO classification for occupational surveillance, and thin-section/HRCT if more anatomical detail or a differential diagnosis is needed; (d) consider BAL, transbronchial biopsy, and mineral analysis when the exposure/imaging picture is inconsistent or an alternative diagnosis matters, rather than treating biopsy as universally required. The 2024 European pathology working group specifically supports cross-disciplinary review and electron-microscopic mineral analysis in difficult mixed-exposure cases. (escuissato2017pulmonarytalcosiscaused pages 1-2, calabrese2024theroleof pages 1-2, calabrese2024theroleof pages 17-19)

Imaging and pathology. Inhalational reports describe small centrilobular and subpleural nodules, ground-glass foci, and, with advanced disease, conglomerate fibrosis; CT distribution cannot alone identify exposure route. IV granulomatosis often has perivascular/centrilobular nodules, sometimes tree-in-bud appearances; high-attenuation masses can occur by either route. Tissue shows polarized-light-birefringent foreign material with macrophages/giant cells and fibrosis; locating material near vessels favors IV embolization, whereas an inhalation history and dust-associated interstitial pattern favor occupational disease. Mineral identification and, when relevant, assessment for silica or asbestos improve attribution. A 2024 imaging review stresses that aspiration and talc granulomatosis may be indistinguishable on CT without history and BAL. Lassandro et al., January 2024, https://doi.org/10.3390/jpm14020134; Calabrese et al., online 20 July 2024, https://doi.org/10.1007/s00428-024-03845-1. (calabrese2024theroleof pages 3-5, escuissato2017pulmonarytalcosiscaused pages 1-2, lassandro2024noninfectiousgranulomatouslung pages 11-14, franquet2021noninfectiousgranulomatouslung pages 7-9, calabrese2024theroleof pages 1-2)

Differential: silicosis, asbestosis, mixed-dust pneumoconiosis, sarcoidosis, chronic beryllium disease where relevant, infectious granulomas including tuberculosis and fungi, aspiration, and other occupational or drug-associated foreign-body lung diseases. For IV-associated cases, consider septic emboli and pulmonary vascular disease. Routine blood tests and echocardiography are for alternatives/complications, not specific talcosis assays; the 2017 IV case had negative BAL cultures and normal echocardiography despite diagnostic biopsy. There is no validated circulating biomarker or molecular/omics diagnostic for talc pneumoconiosis. WGS, WES, gene panels, single-gene tests, CMA, karyotype, FISH, mitochondrial sequencing, and repeat-expansion tests are not indicated to establish this exposure-defined diagnosis. Screening applies to exposed workers, not newborns, carriers, or the general population. (escuissato2017pulmonarytalcosiscaused pages 1-2, lassandro2024noninfectiousgranulomatouslung pages 11-14, calabrese2024theroleof pages 17-19)

11. Outcome and prognosis

Disease burden includes long-term breathlessness, reduced exercise capacity and work ability, chronic cough, impaired gas transfer and, in advanced cases, fibrotic respiratory failure or pulmonary hypertension/right-heart disease. No talc-specific 5-/10-year survival, life-expectancy estimate, disability rate, or validated EQ-5D/SF-36 distribution was identified. Exposure intensity, fibrosis burden, co-inhaled quartz/asbestos, and smoking are reasonable clinical risk descriptors, not independently validated patient-level talcosis prognostic coefficients. The single IV patient above remained stable for three years; that observation is not a recovery rate. (escuissato2017pulmonarytalcosiscaused pages 1-2, antao2006lungdiseasesassociated pages 11-12, calabrese2024theroleof pages 17-19)

The pooled miner/miller mortality estimate for non-malignant respiratory disease was SMR 1.80 (95% CI 1.15–2.82) in the displayed results table; its abstract/nearby prose rounds the same point estimate to 1.81. Pooled lung-cancer mortality SMR was 1.42 (1.07–1.89), but smoking, radon, diesel exhaust and mixed minerals complicate attribution, and an excess of lung cancer is not equivalent to talcosis as a malignant disease. Mesothelioma could not be reliably meta-analyzed. Other reviews reach differing conclusions on inhaled talc and pulmonary carcinogenicity; do not equate asbestos-contaminated and demonstrably asbestos-free material. (ciocan2022riskofmortality pages 6-8, ciocan2022riskofmortality pages 1-2, ciocan2022riskofmortality pages 8-10, lynch2022systematicreviewof pages 8-9)

12. Treatment

Strategy: first eliminate or substantially reduce the responsible exposure, document co-exposures, and treat measurable respiratory problems and comorbidities. Monitor symptoms, oxygenation, lung function and imaging as clinically indicated. Supplemental oxygen for qualifying hypoxemia, pulmonary rehabilitation for reduced exercise tolerance, and treatment of coexisting airflow obstruction or infection are supportive extrapolations from general interstitial/occupational lung-disease practice; none removes deposited talc or has a demonstrated talc-specific response rate. A transplant assessment may be considered for exceptional end-stage disease, but case-report discussion of transplantation predominantly concerns IV talcosis, not an established occupational talcosis treatment pathway. Steroids/immunosuppressants have no established disease-modifying benefit for talc granulomatosis. (escuissato2017pulmonarytalcosiscaused pages 1-2, calabrese2024theroleof pages 1-2, calabrese2024theroleof pages 17-19)

IV-specific management: stop injecting crushed tablets and address substance use; assess and treat associated pulmonary hypertension in specialist care. Sildenafil/oxygen were used in a 2025 IV-excipient case, not tested as occupational pneumoconiosis therapy. One stable 2017 IV case received no disease-specific treatment. Suggested NCIT intervention labels, with numeric codes requiring ontology verification: exposure avoidance, smoking cessation, oxygen therapy, pulmonary rehabilitation, lung transplantation; IV-only, substance-use treatment and pulmonary-hypertension therapy. No talc-specific pharmacogenomic, gene/cell/RNA, immunotherapy, or personalized-genotype treatment exists in the evidence reviewed. (nagarajan2025pulmonaryarterialhypertension pages 4-5, nagarajan2025pulmonaryarterialhypertension pages 2-4, escuissato2017pulmonarytalcosiscaused pages 1-2)

Clinical-trial interpretation matters. Registry NCT05288179, first posted 21 March 2022, studies pirfenidone for pneumoconiosis, with 272 planned participants over 52 weeks, but eligibility specifies silicosis or coal-worker pneumoconiosis—not talc pneumoconiosis. Its results therefore cannot be cited as a talcosis response rate or evidence of an approved talcosis drug. A separately retrieved coal-worker pirfenidone trial, NCT04461587, is similarly not talc-specific. No interventional talc-pneumoconiosis trial was identified by the targeted search. (NCT05288179 chunk 1)

13. Prevention

Primary: characterize the actual talc source and co-minerals; reduce generation and inhalation of respirable dust by process enclosure, effective local exhaust/ventilation, improved drilling and wet methods when feasible, appropriate respiratory protection, and exposure measurement. The talc-miner meta-analysis explicitly recommends improving ventilation and drilling procedures. Avoid IV injection of oral tablets to prevent the separate embolic condition. Secondary: occupational-exposure histories, respiratory questionnaires, spirometry and appropriately interpreted chest radiographs in at-risk workers; investigate changes rather than waiting for severe fibrosis. Tertiary: remove continuing exposure, manage hypoxemia and comorbid respiratory disease, rehabilitate, and address pulmonary hypertension if present. Benefits of particular talc-specific screening intervals or exposure-limit thresholds were not quantified in the retrieved studies. No talcosis vaccine, chemoprophylaxis, carrier screening, prenatal testing, or genetic counseling program is indicated. (escuissato2017pulmonarytalcosiscaused pages 1-2, antao2006lungdiseasesassociated pages 11-12, calabrese2024theroleof pages 17-19, ciocan2022riskofmortality pages 8-10)

14. Other species and natural disease

Naturally occurring talc pneumoconiosis in a specific nonhuman species or breed was not established in the retrieved literature. Consequently, no veterinary breed-ontology term, natural-disease prevalence, or orthologous disease gene can responsibly be assigned. It is a noninfectious exposure-associated condition with no zoonotic or animal-to-human transmission pathway. Experimental cross-species responses are addressed below and should not be mistaken for naturally occurring veterinary disease. (sato2020analysisofparticles pages 1-2, rosenman2012talc pages 4-6)

15. Model organisms

Hamster, Mesocricetus auratus—experimental induced model. Sato et al. reanalyzed particles and lavage material from male hamsters after a single intratracheal talc instillation with assessments over 1–14 days. Quartz, asbestos fibers and toxic-metal particulates were below detection in the original talc sample, although 22% of instilled particles meeting an aspect-ratio ≥3:1 definition were mainly fibrous talc. Macrophages, neutrophils and giant cells contained particles; talc caused acute inflammation and distinctive particle-handling changes. It demonstrates inflammatory plausibility, not chronic occupational latency or human fibrosis incidence. Sato et al., June 2020, https://doi.org/10.1186/s12989-020-00356-0. Exact abstract quote: “talc, even without asbestos and other known toxic contaminants, may elicit inflammation and contribute to lung disease.” (sato2020analysisofparticles pages 1-2, sato2020analysisofparticles pages 13-14)

Rat and mouse—experimental inhalation. A historical National Toxicology Program experiment, summarized in the retrieved toxicology chapter, exposed F344/N rats and B6C3F1 mice to 0, 6 or 18 mg/m³ nonfibrous talc free of identified silica/asbestos, 6 h/day, 5 days/week for approximately two years. Rats developed exposure-associated chronic lung inflammation, collagen accumulation/fibrosis and functional impairment; mice showed more limited changes. A shorter 20-day rat/mouse inhalation experiment at 0, 2, 6 or 18 mg/m³ was described as producing limited macrophage changes without exposure-related lesions. Different duration, dose, animal species, particle morphology, and deposition route explain why apparently discrepant models must not be merged into one human risk estimate. The talc-specific experimental models are useful for particle persistence, phagocyte recruitment and fibrosis but do not reproduce a worker’s complex co-exposures or duration. No validated talcosis-specific knockout/knock-in, zebrafish, organoid, iPSC, or humanized genetic model was identified. (lynch2022systematicreviewof pages 5-6, rosenman2012talc pages 4-6)

Evidence and curation note. The principal 2023–2024 additions retrieved were a 2024 European occupational-pathology expert opinion and 2024 HRCT differential review; the most informative direct talc-specific human observations and controlled animal exposures are older. Reviews supply context, whereas the 2017 IV patient and 2020 hamster analyses are primary reports. For database import, maintain fields for inhalation versus injection, talc mineralogy/co-contaminants, original versus secondary evidence, and unverified ontology IDs; do not assign phenotype frequencies, cancer risks, genetic causes, or therapeutic efficacy to pure occupational talc pneumoconiosis when their evidence comes from mixed-dust cohorts or IV-excipient cases. (calabrese2024theroleof pages 3-5, escuissato2017pulmonarytalcosiscaused pages 1-2, sato2020analysisofparticles pages 1-2, lassandro2024noninfectiousgranulomatouslung pages 11-14, ciocan2022riskofmortality pages 2-4)

References

(calabrese2024theroleof pages 3-5): Fiorella Calabrese, M. Angeles Montero-Fernandez, Izidor Kern, Federica Pezzuto, Francesca Lunardi, Paul Hofman, Sabina Berezowska, Richard Attanoos, Louise Burke, Paola Mason, Elisabetta Balestro, Maria Molina Molina, Chiara Giraudo, Helmut Prosch, Luka Brcic, and Francoise Galateau-Salle. The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the european society of pathology pulmonary pathology working group. Virchows Archiv, 485:173-195, Jul 2024. URL: https://doi.org/10.1007/s00428-024-03845-1, doi:10.1007/s00428-024-03845-1. This article has 22 citations and is from a peer-reviewed journal.
(antao2006lungdiseasesassociated pages 11-12): VC Antao, JE Parker, and GA Pinheiro. Lung diseases associated with silicates and other dusts. Unknown journal, 2006.
(lassandro2024noninfectiousgranulomatouslung pages 11-14): Giulia Lassandro, Stefano Giusto Picchi, Antonio Corvino, Candida Massimo, Stefania Tamburrini, Laura Vanore, Giovanna Urraro, Giuseppe Russo, and Francesco Lassandro. Noninfectious granulomatous lung disease: radiological findings and differential diagnosis. Journal of Personalized Medicine, 14:134, Jan 2024. URL: https://doi.org/10.3390/jpm14020134, doi:10.3390/jpm14020134. This article has 9 citations.
(ciocan2022riskofmortality pages 6-8): Catalina Ciocan, Alessandro Godono, Sandro Stefanin, Paolo Boffetta, Enrico Pira, and Marco Clari. Risk of mortality from respiratory malignant and non-malignant diseases among talc miners and millers: a systematic review and meta-analysis. Toxics, 10:589, Oct 2022. URL: https://doi.org/10.3390/toxics10100589, doi:10.3390/toxics10100589. This article has 6 citations.
(ciocan2022riskofmortality pages 1-2): Catalina Ciocan, Alessandro Godono, Sandro Stefanin, Paolo Boffetta, Enrico Pira, and Marco Clari. Risk of mortality from respiratory malignant and non-malignant diseases among talc miners and millers: a systematic review and meta-analysis. Toxics, 10:589, Oct 2022. URL: https://doi.org/10.3390/toxics10100589, doi:10.3390/toxics10100589. This article has 6 citations.
(ciocan2022riskofmortality pages 2-4): Catalina Ciocan, Alessandro Godono, Sandro Stefanin, Paolo Boffetta, Enrico Pira, and Marco Clari. Risk of mortality from respiratory malignant and non-malignant diseases among talc miners and millers: a systematic review and meta-analysis. Toxics, 10:589, Oct 2022. URL: https://doi.org/10.3390/toxics10100589, doi:10.3390/toxics10100589. This article has 6 citations.
(ciocan2022riskofmortality pages 8-10): Catalina Ciocan, Alessandro Godono, Sandro Stefanin, Paolo Boffetta, Enrico Pira, and Marco Clari. Risk of mortality from respiratory malignant and non-malignant diseases among talc miners and millers: a systematic review and meta-analysis. Toxics, 10:589, Oct 2022. URL: https://doi.org/10.3390/toxics10100589, doi:10.3390/toxics10100589. This article has 6 citations.
(escuissato2017pulmonarytalcosiscaused pages 1-2): Dante Luiz Escuissato, Rimarcs Gomes Ferreira, João Adriano de Barros, and Edson Marchiori. Pulmonary talcosis caused by intravenous methadone injection. Jornal Brasileiro de Pneumologia, 43:154-155, Apr 2017. URL: https://doi.org/10.1590/s1806-37562016000000337, doi:10.1590/s1806-37562016000000337. This article has 10 citations and is from a peer-reviewed journal.
(sato2020analysisofparticles pages 1-2): Erika Sato, Sandra A. McDonald, Yuwei Fan, Shaina Peterson, Joseph D. Brain, and John J. Godleski. Analysis of particles from hamster lungs following pulmonary talc exposures: implications for pathogenicity. Particle and Fibre Toxicology, Jun 2020. URL: https://doi.org/10.1186/s12989-020-00356-0, doi:10.1186/s12989-020-00356-0. This article has 13 citations and is from a domain leading peer-reviewed journal.
(sato2020analysisofparticles pages 13-14): Erika Sato, Sandra A. McDonald, Yuwei Fan, Shaina Peterson, Joseph D. Brain, and John J. Godleski. Analysis of particles from hamster lungs following pulmonary talc exposures: implications for pathogenicity. Particle and Fibre Toxicology, Jun 2020. URL: https://doi.org/10.1186/s12989-020-00356-0, doi:10.1186/s12989-020-00356-0. This article has 13 citations and is from a domain leading peer-reviewed journal.
(calabrese2024theroleof pages 1-2): Fiorella Calabrese, M. Angeles Montero-Fernandez, Izidor Kern, Federica Pezzuto, Francesca Lunardi, Paul Hofman, Sabina Berezowska, Richard Attanoos, Louise Burke, Paola Mason, Elisabetta Balestro, Maria Molina Molina, Chiara Giraudo, Helmut Prosch, Luka Brcic, and Francoise Galateau-Salle. The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the european society of pathology pulmonary pathology working group. Virchows Archiv, 485:173-195, Jul 2024. URL: https://doi.org/10.1007/s00428-024-03845-1, doi:10.1007/s00428-024-03845-1. This article has 22 citations and is from a peer-reviewed journal.
(franquet2021noninfectiousgranulomatouslung pages 7-9): Tomás Franquet, Teri J. Franks, Jeffrey R. Galvin, Edson Marchiori, Ana Giménez, Sandra Mazzini, Takeshi Johkoh, and Kyung Soo Lee. Non-infectious granulomatous lung disease: imaging findings with pathologic correlation. Korean Journal of Radiology, 22:1416-1435, May 2021. URL: https://doi.org/10.3348/kjr.2020.1082, doi:10.3348/kjr.2020.1082. This article has 21 citations and is from a peer-reviewed journal.
(rosenman2012talc pages 1-2): Kenneth D. Rosenman. Talc. Patty's Toxicology, pages 257-272, Aug 2012. URL: https://doi.org/10.1002/0471435139.tox013.pub2, doi:10.1002/0471435139.tox013.pub2. This article has 1 citations.
(NCT05288179 chunk 1): Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis. Beijing Continent Pharmaceutical Co, Ltd.. 2022. ClinicalTrials.gov Identifier: NCT05288179
(calabrese2024theroleof pages 17-19): Fiorella Calabrese, M. Angeles Montero-Fernandez, Izidor Kern, Federica Pezzuto, Francesca Lunardi, Paul Hofman, Sabina Berezowska, Richard Attanoos, Louise Burke, Paola Mason, Elisabetta Balestro, Maria Molina Molina, Chiara Giraudo, Helmut Prosch, Luka Brcic, and Francoise Galateau-Salle. The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the european society of pathology pulmonary pathology working group. Virchows Archiv, 485:173-195, Jul 2024. URL: https://doi.org/10.1007/s00428-024-03845-1, doi:10.1007/s00428-024-03845-1. This article has 22 citations and is from a peer-reviewed journal.
(rosenman2012talc pages 6-7): Kenneth D. Rosenman. Talc. Patty's Toxicology, pages 257-272, Aug 2012. URL: https://doi.org/10.1002/0471435139.tox013.pub2, doi:10.1002/0471435139.tox013.pub2. This article has 1 citations.
(rosenman2012talc pages 4-6): Kenneth D. Rosenman. Talc. Patty's Toxicology, pages 257-272, Aug 2012. URL: https://doi.org/10.1002/0471435139.tox013.pub2, doi:10.1002/0471435139.tox013.pub2. This article has 1 citations.
(nagarajan2025pulmonaryarterialhypertension pages 2-4): Keerthana Nagarajan, Jacinth Preethi, Sathya A, Rangaswami M, and Chandrasekar Selvaraj. Pulmonary arterial hypertension due to talc granulomatosis following intravenous use of oral medications: a report of a rare case. Cureus, Jul 2025. URL: https://doi.org/10.7759/cureus.88887, doi:10.7759/cureus.88887. This article has 3 citations.
(lassandro2024noninfectiousgranulomatouslung media bed83719): Giulia Lassandro, Stefano Giusto Picchi, Antonio Corvino, Candida Massimo, Stefania Tamburrini, Laura Vanore, Giovanna Urraro, Giuseppe Russo, and Francesco Lassandro. Noninfectious granulomatous lung disease: radiological findings and differential diagnosis. Journal of Personalized Medicine, 14:134, Jan 2024. URL: https://doi.org/10.3390/jpm14020134, doi:10.3390/jpm14020134. This article has 9 citations.
(lynch2022systematicreviewof pages 8-9): Heather N. Lynch, Daniel J. Lauer, William J. Thompson, Olivia Leleck, Rachel D. Freid, Justin Collins, Kathleen Chen, A. Michael Ierardi, Ania M. Urban, Michael A. Cappello, Paolo Boffetta, and Kenneth A. Mundt. Systematic review of the scientific evidence of the pulmonary carcinogenicity of talc. Frontiers in Public Health, Oct 2022. URL: https://doi.org/10.3389/fpubh.2022.989111, doi:10.3389/fpubh.2022.989111. This article has 20 citations.
(nagarajan2025pulmonaryarterialhypertension pages 4-5): Keerthana Nagarajan, Jacinth Preethi, Sathya A, Rangaswami M, and Chandrasekar Selvaraj. Pulmonary arterial hypertension due to talc granulomatosis following intravenous use of oral medications: a report of a rare case. Cureus, Jul 2025. URL: https://doi.org/10.7759/cureus.88887, doi:10.7759/cureus.88887. This article has 3 citations.
(lynch2022systematicreviewof pages 5-6): Heather N. Lynch, Daniel J. Lauer, William J. Thompson, Olivia Leleck, Rachel D. Freid, Justin Collins, Kathleen Chen, A. Michael Ierardi, Ania M. Urban, Michael A. Cappello, Paolo Boffetta, and Kenneth A. Mundt. Systematic review of the scientific evidence of the pulmonary carcinogenicity of talc. Frontiers in Public Health, Oct 2022. URL: https://doi.org/10.3389/fpubh.2022.989111, doi:10.3389/fpubh.2022.989111. This article has 20 citations.

Artifacts

Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.3.0.

Outcome	Count
References checked	11
Resolved	11
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	11
On topic	3
Off topic	1

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

DOI:10.1002/0471435139.tox013.pub2 (7 mentions) - Talc
shared terms: talc

Weighed against this report's own most characteristic terms: disease, exposure, talc, clinical, gene, pulmonary, genetic, occupational, pneumoconiosis, fibrosis, cell, ontology, primary, respiratory, talc-specific, talcosis, type, validated, year, treatment.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	1
Resolved	1
Unresolved (possible confabulation)	0
Obsolete	0
Unverifiable	0
Terms whose name was checked	1
Terms named correctly	0
Terms named as a different term	1

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

MONDO:0001003 (2 mentions) - the report calls it "if available"; MONDO calls it pneumoconiosis due to talc

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Definitions

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Medical Actions

Environmental Factors

Progression

Differential Diagnoses

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Talc pneumoconiosis: disease-characteristics research report

1. Disease information

2. Etiology and risk or protective factors

3. Phenotypes and suggested HPO terms

4. Genetic and molecular information

5. Environmental information

6. Mechanism and pathophysiology

7. Anatomical structures affected

8. Temporal development

9. Inheritance, population and epidemiology

10. Diagnostics

11. Outcome and prognosis

12. Treatment

13. Prevention

14. Other species and natural disease

15. Model organisms

Artifacts

Reference Validation

References that may not be about this subject

Term Validation

Terms the report names something else